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1. INTRODUCTION 
 
Human transcriptome analysis has revealed the existence of a surprisingly high 
number of noncoding RNAs that have been classified in multiple families based on their 
size and biogenesis. Long non-coding RNAs (lncRNAs) are defined as transcripts longer 
than 200 nucleotides transcribed by RNA polymerase II and commonly originated from 
intergenic regions. LncRNAs can be capped, spliced, and polyadenylated and usually show 
limited protein coding potential (Jandura & Krause, 2017; Kopp & Mendell, 2018 and 
literature cited therein). 
LncRNAs are emerging as a fundamental aspect of biology due to their ability to 
reprogram gene expression and influence distinct cellular functions including cell fate 
determination, cell cycle progression, apoptosis, and aging (Jandura & Krause, 2017; Kopp 
& Mendell, 2018). Their expression is usually tissue restricted, developmentally regulated, 
and can change under specific pathological conditions. Many lncRNAs influence 
hallmarks of cancer such as uncontrollable proliferation, evasion of cell death, as well as 
metastasis formation and it has been suggested that lncRNAs can act as oncogenes or 
tumor suppressors —either directly or indirectly— by interfering with different pathways 
(Long et al., 2017; Arun et al., 2018).  
From a mechanistic point of view, lncRNAs may influence the function of 
transcriptional complexes, modulate chromatin structures, function as scaffolds to form 
ribonucleoprotein (RNP) complexes as well as act as decoys for proteins and micro-RNAs 
(miRNAs) (Long et al., 2017; Kopp & Mendell, 2018). Thus, lncRNA-mediated control of 
gene expression may take place at transcriptional and/or post-transcriptional levels (Gupta 
et al., 2010; Yoon et al., 2012; Geisler & Coller, 2013; Cao et al., 2017; Long et al., 2017). 
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Recently, lncRNAs have been described as important components of the Transforming 
Growth Factor β (TGF-β) signaling pathway (Yuan et al., 2014; Dhamija & Diederichs, 
2016). TGF-β belongs to a large family of structurally related cytokines that regulate 
growth, survival, differentiation, and migration of many cell types including mammary 
gland epithelial cells (ref. Shi & Massague (2003) for a review). TGF-β activates 
membrane kinase receptors and induces phosphorylation of cell-specific SMAD proteins 
that, in complex with the common SMAD4, accumulate into the nucleus to regulate gene 
expression at different levels (ref. Budi et al. (2017) for a recent review). 
In our previous studies, we showed that the multifunctional RNA binding protein 
KHSRP acts as a regulatory hub that conveys extracellular stimuli resulting into gene 
expression changes due to its ability to interact with several molecular partners (Briata et 
al., 2016). KHSRP is able to post-transcriptionally regulate gene expression by promoting 
decay of unstable mRNAs, favoring maturation of select miRNAs from precursors, and 
controlling alternative splicing events (Briata et al., 2016).  
Recently, we reported that KHSRP controls the alternative splicing of a cohort of pre-
mRNAs that encode regulators of cell adhesion and motility —such as CD44 and 
FGFR2— favoring their “epithelial type” exon usage, and that miRNA-mediated KHSRP 
silencing is required for TGF-β-induced Epithelial-to-Mesenchymal Transition (EMT) in 
immortalized NMuMG mammary gland cells (Puppo et al., 2016). Further, we found that 
Resveratrol - a natural polyphenolic compound endowed with anti-inflammatory, anti-
proliferative, as well as pro-apoptotic activities- prevents TGF-β-dependent KHSRP down-
regulation thus shifting Cd44 and Fgfr2 pre-mRNA alternative splicing from the 
mesenchymal-specific to the epithelial-specific isoform (Moshiri et al., 2017).  
7 
 
Our previous observation that the lncRNA H19 interacts with KHSRP and affects its 
mRNA decay promoting function (Giovarelli et al., 2014) prompted us to identify 
additional KHSRP/lncRNAs interactions endowed with regulatory potential. 
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2. BACKGROUND OF THE STUDY 
 
2.1  RNA: Messenger, Enzyme, Regulator 
The central dogma of molecular biology suggested that DNA contains the information 
to encode proteins and that three different types of RNA rather passively convert this code 
into polypeptides. Specifically, messenger RNA (mRNA) carries the protein blueprint from 
a cell's DNA to the ribosomes which drive protein synthesis. Transfer RNA (tRNA)  
carries the appropriate amino acids into the ribosomes for inclusion in the new protein and 
the ribosomes themselves consist largely of ribosomal RNA (rRNA) molecules (Clancy, 
2008). However, since the structure of DNA was first described, scientists have learned 
that RNA does much more than simply playing a role in protein synthesis. For example, 
many types of RNA have been found to be catalytic - that is, they carry out biochemical 
reactions just like enzymes do (Clancy, 2008). The condensation of amino acids in the 
peptidyl transferase center of the ribosome is catalyzed by the major RNA component of 
the large subunit and the splicing of mRNA in eukaryotes is catalyzed by the U2-U6 small 
nuclear RNAs found within the splicing speckles. (Wilson and Lilley, 2015).  
Further, several RNA molecules have been found to play complex regulatory roles in 
cell (Clancy, 2008). As a group, these RNAs are frequently referred to as regulatory RNAs, 
and, in eukaryotes, they have been further classified into a number of subcategories. 
Regulatory noncoding RNAs (ncRNAs) can be divided into two main different classes, 
small RNAs and long noncoding RNAs (lncRNAs). lncRNAs are usually defined as poly-
adenylated RNA transcripts several hundred nucleotides long while the smallRNAs are in 
the range of 20-30 nucleotides.  
RNA is in fact emerging as a major component of the regulatory circuitry that 
underpins the development and physiology of complex organisms. Defects in certain 
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RNAs have been implicated in a number of important human diseases, including heart 
disease, cancer, stroke and many others (Clancy, 2008). 
 
2.1.1 RNA in Gene Expression Regulation 
Protein production is regulated in multiple, diverse ways which all act in a controlled 
and dynamic manner in what we collectively call ‘gene expression regulation’. RNA plays 
an active role at different levels of gene expression regulation. 
There are many steps in the pathway leading from DNA to protein and we now know 
that all of them can in principle be regulated (Alberts et al (2007) for a complete review; 
Fig I)  
A cell can control the proteins it makes by: 
• controlling when and how often a given gene is transcribed (transcriptional control) 
• controlling the splicing and processing of RNA transcripts (RNA processing control) 
• controlling the localization of the RNA molecules (RNA transport and localization 
control) 
• controlling the way mRNAs are translated at the ribosome sites (translational 
control) 
• Controlling the stability of certain mRNA molecules (mRNA degradation control) 
• selectively activating, inactivating, degrading, or locating specific protein molecules 
after they have been produced (protein activity control). 
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Fig. I.  Six steps at which eukaryotic gene expression can be controlled 
(Alberts et al., 2007). 
 
In general, regulatory RNAs can control gene expression at the transcriptional and 
post-transcriptional level (Kaikkonen et al., 2011).  
One widely known example of RNA-mediated transcriptional regulation is the role of 
X-inactive specific transcript (Xist) in X-chromosome inactivation. The large Xist 
transcript is expressed on the inactive chromosome and not on the active one and the 
chromosome coating by Xist is essential for inactivation.  
MicroRNAs (miRNAs) are major members of regulatory RNAs playing an important 
role at the post-transcriptional level of gene expression. These short ncRNAs bind to a 
specific target messenger RNA with a complementary sequence in order to induce its 
degradation or block protein translation (Bartel, 2004, for a review). 
The continual discovery of new regulatory RNA species suggests that we are only just 
beginning to understand their complexity and functions.  
 
2.2 Non-coding RNAs: Form, Function, Physiology 
Following the sequencing of the human genome, focus has shifted toward 
understanding gene function. In 2005, the FANTOM (Functional Annotation of Mammals) 
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Consortium determined that the genome harbors more non-coding genes than coding genes 
(Carninci et al., 2005). The ENCyclopedia Of DNA Elements (ENCODE) Consortium, 
revealed that only 2-3-% of the mammalian genome is transcribed into protein-coding 
RNAs (Birney et al., 2007). The other 98% has been considered for a long time as inactive 
material, regions of several mega-bases without any function, so-called “junk DNA” (Taft 
et al., 2007). However, the overwhelming development of high-density micro-arrays and 
high-throughput sequencing technologies, as well as bioinformatics analyses, has revealed 
that non-coding transcripts are major regulators of gene expression. The examples given 
above regarding the lncRNA Xist and the miRNAs show the importance of noncoding  
species in modulating gene expression (for other references see Rinn & Chang, 2012; Sole 
et al., 2015; De Andres-Pablo et al., 2017). “Non-coding RNA” is a broad definition that 
encompasses all types of RNA that lack empirical evidence of translation into protein 
although recent evidence revealed that certain short Open Reading Frames (ORF) of 
ncRNAs are actually translated into small peptides (Slavoff et al., 2013). NcRNAs come in 
many forms, perform diverse functions, and play critical roles in health and disease. Tens 
of thousands of ncRNAs have been identified so far, but we are still at the earliest stages of 
understanding their regulation and functions. Such knowledge will be critical in order to 
harness the full potential of non-coding RNAs for the diagnosis and treatment of human 
diseases (Delás & Hannon 2017). 
 
2.2.1 LncRNA functions in gene expression 
LncRNAs are highly heterogeneous molecules and have a substantial functional 
versatility that relies on different structures and interactions. Among the variety of 
mechanisms involved in gene expression regulation, many lncRNAs have been shown to 
interact with chromatin-modifying complexes (Rinn & Chang, 2012; Bierhoff et al., 2014; 
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Marchese & Huarte, 2014; Engreitz et al., 2016), while others have been shown to interfere 
with the transcriptional machinery (Prasanth et al., 2005; Clemson et al., 2009; Sunwoo et 
al., 2009). Furthermore, some lncRNAs mediate key steps in post-transcriptional regulation 
of gene expression  (Yoon et al., 2013; Quinn & Chang, 2016). 
 
2.2.2 LncRNAs as chromatin regulators 
A large repertoire of lncRNAs is able to interact with chromatin-modifying complexes 
and these lncRNA-containing complexes can promote either selective repression or 
activation of genes (Gendrel & Heard, 2014; Marchese & Huarte, 2014; Morlando et al., 
2014;  Meller & Joshi, 2015). For instance, several lncRNAs have been shown to recruit 
histone H3K4 methyltransferases in order to promote activation of gene expression (Wang 
et al., 2011; Cabianca et al., 2012; Grote et al., 2013). Others bind DNA 
methyltransferases, such as DNMT1 and DNMT3b, and repress transcription by promoting 
DNA methylation (Mohammad et al., 2010; Schmitz et al., 2010; Johnsson et al., 2013). 
Finally, many lncRNAs have been shown to interact with the polycomb repressive 
complex 2 (PRC2), which catalyses generation of the H3K27me3 silencing mark (Rinn et 
al., 2007; Khalil et al., 2009; Shore et al., 2012; Grote et al., 2013; Marin-Bejar et al., 
2013; Kotzin et al., 2016; Wang et al., 2016). PRC2 is the most studied chromatin complex 
with respect to the functional role of lncRNAs in the epigenetic regulation of gene 
expression (Davidovich & Cech, 2015). 
The activity of several noncoding RNAs is tightly connected to their own site of 
transcription. These lncRNAs remains in the proximity of their own locus and associate 
with complexes that determine a local regulation of gene expression (cis-regulation) 
(Engreitz et al., 2013). Other lncRNAs, instead, act as a platform for trans-chromosomal 
interactions. In this context, the cooperative association of lncRNAs with other RNAs and 
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proteins is significant for acting at distant genomic loci (trans-regulation) (Hacisuleyman 
et al., 2014). 
 
2.2.3 LncRNAs as modulators of Transcription Factors 
Among the proteins that can be modulated by lncRNAs are the transcription factors - 
the key players of transcriptional regulation (Marchese et al., 2017). In the most canonical 
model, gene expression control is thought to be mediated by transcription factors, whose 
activation is usually regulated by signalling pathways and whose DNA-binding ability is 
associated with sequence specificity (Marchese et al., 2017). Several lncRNAs have been 
reported to bind transcription factors in order to regulate gene expression. As an example, a 
lncRNA, named ‘damage-induced noncoding RNA’ (DINO), was identified in the 
regulation of the DNA-damage-induced p53 response (Schmitt et al., 2016). The results 
support the notion that p53 can bind simultaneously DNA and RNA and ascribe to the 
lncRNA DINO a regulatory role in p53-mediated gene expression (Schmitt et al., 2016). 
The possibility that a lncRNA can bind and regulate transcription factors or chromatin 
remodeling complexes confers numerous advantages to the cell (Marchese et al., 2017). 
For instance, lncRNAs are known to be highly cell and tissue specific (Cabili et al., 2011; 
Cabili et al., 2015) which means that, without changing the transcriptional machinery, cell- 
and tissue-specific regulation of gene expression could be achieved (Marchese et al., 
2017). LncRNA-dependent regulation could also be considered in terms of cost-
effectiveness, as RNAs are energetically less expensive to be produced in comparison with 
proteins. Also, lncRNAs are more rapidly produced than proteins in response to stimuli 
and this could confer faster cellular responses. Moreover, they can act locally at their site 
of transcription, whereas proteins need to be translated from their encoding RNAs in the 
cytoplasm and be returned to the nucleus (Marchese et al., 2017).  
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2.2.4 Post-transcriptional regulation by lncRNAs.  
Although the majority of characterized lncRNAs are directly involved in 
transcriptional regulation, different lncRNAs have been implicated in the splicing, 
turnover, export or translation of mRNAs, as well as in the stability and post-translational 
modification of proteins (Huarte, 2015). An example of the latter is the lncRNA Breast 
Cancer Anti-estrogen Resistance 4 (BCAR4), the expression of which correlates with 
metastatic advanced breast cancer and anti-estrogen resistance (Godinho et al, 2011; Xing 
et al., 2014). BCAR4 promotes the acetylation of Smad nuclear interacting protein 1 
(SNP1) and serine/threonine-protein phosphatase 1 regulatory subunit 10 (PNUTS), thus 
activating the hedgehog/GLI2 transcriptional program and promoting cell migration (Xing 
et al., 2014; Huarte, 2015).  
Alternative splicing is another mechanism by which lncRNAs can influence post-
transcriptional regulation and cancer progression (Huarte, 2015). Indeed, many mRNA-
splicing isoforms are developmentally regulated, and they are preferentially re-expressed 
in tumors. (Huarte, 2015). The lncRNA Zeb2-NAT controls translation and therefore 
function of the ZEB2 protein coding gene through regulation of Zeb2mRNA splicing. 
Splicing inhibition allows translation of ZEB2, a transcriptional repressor of E-cadherin. 
Further, some lncRNAs function as RNA sponges, basing their activity on sequence-
specific interactions with other RNAs (Salmena et al., 2011). For instance, the cytoplasmic 
lncRNA Phosphatase and TENsin homolog Pseudogene 1 (PTENP1) binds to microRNAs 
that otherwise would target PTENmRNA, reducing its expression and tumor suppressor 
activity (Poliseno et al., 2010). This crosstalk between lncRNAs, miRNAs and mRNAs 
highlights the complex fine-tuning of RNA networks. However, these dynamics are still far 
from being completely understood (Huarte, 2015). 
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2.2.5 LncRNAs able to encode proteins and peptides: challenges and 
ambiguities 
 Increasing evidence underlines a series of intriguing translational events from 
lncRNAs which were previously considered to lack protein coding potential (Hube et al., 
2006; Kondo et al., 2010; Ulveling et al., 2011).  Recent studies also suggest that products 
derived from such novel translational events display important regulatory functions in 
many fundamental biological and pathological processes.  
The first report of a bifunctional RNA was the human Steroid Receptor 
Activator (SRA). Originally, SRA was characterized as a ncRNA able to co-activate the 
steroid hormone receptors (Lanz et al., 1999). Remarkably, SRA transcripts have now been 
shown to encode a functional protein (SRAP) which appears to act antagonistically to SRA 
RNA (Chooniedass-Kothari et al., 2006). 
A study by Nelson et. al (2016) described a mammalian muscle-specific lncRNA that 
encodes a peptide of 34 amino acids, named Dwarf Open Reading Frame (DWORF). 
DWORF localizes to the sarcoplasmic reticulum (SR), where it enhances the activity of the 
calcium pump SERCA by displacing SERCA inhibitors (Nelson et al., 2016). Further, 
Anderson et al. (2015) discovered a conserved micropeptide, named myoregulin (MRLN), 
encoded by a skeletal muscle-specific RNA annotated as a putative long noncoding RNA. 
MRLN interacts directly with SERCA and inhibits calcium uptake into the Sarcoplasmic 
Reticulum. These studies identified micropeptides as important regulators of muscle 
physiology and highlighted the possibility that additional peptides are encoded by many 
RNAs currently annotated as noncoding (Anderson et al., 2015; Nelson et al., 2016). More 
recently, Yu et al. (2017) showed that the lncRNA encoding MRLN, named Linc-RAM, 
promotes myogenic differentiation in a MRLN-independent manner (Yu et al., 2017).  
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2.2.6 LncRNAs and Cancer 
It is increasingly evident that many of the genomic mutations in cancer reside inside 
regions that do not encode proteins and these regions are often transcribed into long 
noncoding RNAs (lncRNAs) (Huarte, 2015). The recent application of next-generation 
sequencing to a growing number of cancer transcriptomes has indeed revealed thousands 
of lncRNAs whose aberrant expression is associated with different cancer types. Among 
the few that have been functionally characterized, several have been linked to malignant 
transformation (Fig II).  
One of the best characterized lncRNA is HOX-antisense intergenic RNA (HOTAIR), 
which plays a critical role in chromatin dynamics and gene silencing, and appears to be 
misregulated in a variety of cancers. HOTAIR regulates genes involved in cell cycle 
progression, cell migration, Epithelial to Mesenchimal Transition  (EMT), metastasis, and 
tumor progression (Bhan & Mandal, 2015). Various reports have demonstrated that the 
expression of HOTAIR is significantly upregulated in ER-positive breast tumors and 
correlates with metastasis and progression (Gupta et al., 2010; Lu et al., 2012, Sorensen et 
al., 2013). Studies by Sorensen et al. showed that patients with low HOTAIR expression 
had better survival than those with high HOTAIR expression. (Sorensen et al., 2013). 
The expression of the lncRNA metastasis-associated lung adenocarcinoma transcript 1 
(MALAT1) was also identified early as a prognostic parameter for lung cancer survival. 
MALAT1 expression has now been associated with malignancy in multiple types of 
tumors, including liver, breast and colon, suggesting that it has a general role in cell 
proliferation. MALAT1 is a nuclear lncRNA, highly conserved across mammals and 
extremely abundant in many cell types. It has been linked to the regulation of alternative 
mRNA splicing and the modulation of the epigenetic machinery, and it is known to be 
associated with nascent pre-mRNA of actively transcribed genes. Despite being the subject 
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of intensive study, the role of MALAT1 in cancer is not yet fully understood (Huarte, 
2015). 
 
Fig II.  LncRNAs associated with various cancer types.  
M.M. Balas, A.M. Johnson,  Non-coding RNA Research (2018) 
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2.3 Epithelial To Mesenchymal Transition  
Epithelial to Mesenchymal Transition (EMT) is a biological process which allows 
epithelial cells to lose their characteristics and acquire a mesenchymal phenotype. It has 
recently been proposed that, rather than being a binary process, EMT occurs through 
distinct intermediate states: from epithelial to completely mesenchymal states, passing 
through intermediate hybrid states (Pastushenko et al., 2018). Through EMT, cells gain the 
ability to migrate and resist apoptosis as well as the potential to enter stem cell-like states 
(De Craene and Berx, 2013; Ye and Weinberg, 2015). Phenotypical hallmarks of EMT 
include morphological changes from a cobblestone-like epithelial shape to a spindle-like 
fibroblast phenotype, loss of epithelial CDH1 (also known as E-cadherin) at cell junctions, 
and increased expression of mesenchymal CDH2 (also known as N-cadherin). The 
opposite trans-differentiation process, mesenchymal-to-epithelial transition (MET), is also 
possible (De Craene and Berx, 2013; Ye and Weinberg, 2015).  
Molecular key events in EMT include activation of transcription factors, expression of 
specific cell-surface proteins, reorganization of the cytoskeleton, production of proteases 
degrading the extracellular matrix (ECM), and expression of specific microRNAs. In many 
cases, these factors can be used as biomarkers to demonstrate the passage of a cell through 
EMT. (Fig III). (Kalluri and Weinberg, 2009). 
 
Fig.III.  EMT process and molecular markers 
Kalluri and Weinberg, The Journal of clinical investigation, 2009 
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EMT is involved in many physiological and pathological processes. During 
development, EMT allows implantation, embryo formation, cell differentiation and organ 
development. Moreover, in tissue repair, EMT generates fibroblasts and other related cells 
that contribute to wound healing (Kalluri and Weinberg, 2009). 
Many studies show that the activation of an EMT program also plays an important role 
in tumor progression with cells acquiring the ability to invade and metastasize (Brabletz et 
al., 2001; Thiery, 2002; Fidler & Poste, 2008; Yang & Weinberg, 2008). In secondary 
tumors, carcinoma cells may undergo MET and revert to an epithelial phenotype during the 
colonization process (Zeisberg et al., 2005).  
Recent studies revealed an unexpected role of EMT in cancer chemoresistance 
(Fischer et al., 2015; Zheng et al., 2015), Authors showed that suppressing EMT in mice 
models had no effect on the number of circulating tumor cells or the overall frequency of 
metastasis. However, suppressing EMT enhanced the sensitivity of the tumors to 
chemotherapy drugs, suggesting a role for EMT in cancer drug resistance. (Fischer et al., 
2015; Zheng et al., 2015).  
 
2.3.1 Molecular processes underlying EMT 
EMT-inducing signals derived from the tumor microenvironment, such as TGF β, 
HGF, EGF, PDGF, are responsible for the induction of a series of transcription factors 
driving the EMT process. Once expressed and activated, each transcription factor can act 
pleiotropically to activate and orchestrate the EMT program. Upon the initiation of EMT, 
cell junctions are relocalized and/or degraded. The dissolution of tight junctions during 
EMT is accompanied by decreased claudin and occludin expression, and the diffusion of 
zonula occludens 1 (ZO1; also known as TJP1) from cell–cell contacts. During the 
destabilization of adherens junctions, the epithelial cadherin CDH1 is cleaved at the 
20 
 
plasma membrane and subsequently degraded. The downregulation of CDH1 is balanced 
by the increased expression of the mesenchymal neural cadherin CDH2 that alters cell 
adhesion. During EMT cells lose their apical-basal polarity and acquire a front-rear 
polarity. The cortical actin cytoskeleton is reorganized and cells acquire directional 
motility. EMT progression also requires disruption and reorganization of cell-Extracellular 
Matrix (ECM) interactions. Further, secretion of proteases, like the metalloproteinases 
MMP2 and MMP9, enable ECM degradation and tissues invasion (Kalluri & Weinberg, 
2009, Lamouille, 2014, and literature cited in there). 
EMT progression is also associated with differential splicing of nascent RNAs. 
Alternative splicing modulation in EMT is well illustrated by changes in the isoform 
expression of the adhesion protein CD44 and FGFR2. Indeed, during EMT there is a 
switch from epithelial to mesenchymal splice isoforms of these molecules (Lamouille, 
2014 and literature in it). 
 
2.3.2 Role of TGF-β in EMT 
Among the signaling pathways that initiate EMT, TGF-β family has a predominant 
role. TGF-β family comprises three TGF-βs, two activins, several bone morphogenetic 
proteins (BMPs) and other ligands that all act through binary combinations of 
transmembrane kinase receptors. TGF-β1 is able to induce EMT in development, wound 
healing, fibrosis and cancer (Lamouille et al., 2014).  
Binding of TGF-β to cell surface receptor enables the “type II” TGF-β family 
receptors to phosphorylate and activate the “type I” transmembrane kinases which then 
phosphorylate the C termini of the intracellular signaling effectors SMADs. The receptor-
activated SMAD2 and/or SMAD3 combine with SMAD4 to form trimeric SMAD 
complexes. Following their translocation into the nucleus, SMAD complexes combine with 
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DNA-binding transcription factors at regulatory gene sequences and activate or repress 
transcription (Lamouille et al., 2014). 
 
 
Fig IV Schematic of Smad mediated TGFβ signaling pathway. 
TGFβ ligand binds to TGFβRII/TGFβRI receptors leading to phosphorylation of Smad2/3. Phosphorylated 
Smad2/3 binds to Smad4 to form a protein complex that undergoes nuclear translocation and regulates the 
expression of TGFβ target genes through binding to the Smad-binding element (SBE). 
Han and Wang; Cell & Bioscience 2011 
 
In response to TGF-β, SMAD complexes activate the expression and increase the 
activity of EMT transcription factors like SNAIL1, a master regulator of EMT. SMAD3-
SMAD4 also cooperates with SNAIL1 in response to TGF-β and thus relays the TGF-β-
activated repression of genes encoding, among others, the E-cadherin and the Occludin 
(Vincent et al., 2009).  
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2.4 The Two faces of TGF-β1 in Breast Cancer 
In normal physiological conditions, TGF-β1 is a potent inhibitor of growth of 
epithelial cells. TGF-β1 primarily targets G1 events by regulating the expression of several 
genes promoting cell cycle arrest. Specifically, TGF-β1 mainly activates the transcription 
of cyclin-dependent kinases inhibitors such as p21 (encoded by the CDKN1A gene) and 
p15 (encoded by CDKN2B gene) (Zarzynska, 2014 and references in it).  
The role of TGF-β1 in pathological conditions, specifically in breast cancer, has been 
shown to be multifaceted, dependent on the tumor stage. In early stages of breast cancer 
TGF-β1 inhibits epithelial cell cycle progression and promotes apoptosis, showing tumor 
suppressive effects. In late stages of breast cancer, TGF-β1 changes its action into a tumor 
promoter and several studies have shown a link between TGF-β1 treatment and increased 
tumor progression, higher cell motility, cancer invasiveness and metastasis (Zarzynska, 
2014, and references in it). This is known as “TGF-β1 paradox” and it is still objects of 
deep investigation (Taylor et al., 2010; Parvani et al., 2011).  Elucidation of the molecular 
mechanisms responsible for conferring oncogenic activities of TGF-β1 might provide new 
therapeutic opportunities to alleviate metastatic progression and disease recurrence of 
breast cancer. 
 
2.5 KHSRP 
The single-stranded nucleic acid binding protein KHSRP (K Homology -type splicing 
regulatory protein) modulates RNA life and gene expression at multiple levels and controls 
important cellular functions such as proliferation, differentiation and EMT. (Briata, 2016 
for a review). 
On the structural level, KHSRP is a 75-KDa protein organized in three distinct regions 
(Fig V): a central region that includes four KH domains responsible for nucleic acid 
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binding and two N- and C- terminal regions, respectively, that contain several sites for 
post-translational modification as well as protein interaction motifs. This modular structure 
and the resulting binding flexibility allow the protein to interact with multiple targets in 
order to regulate gene expression (García-Mayoral et al., 2007). 
 
 
Fig. V. Schematic representation of the primary structure of human KHSRP 
Gherzi et al., WIREs RNA, 2010 
 
KHSRP plays an important role in post-transcriptional gene expression regulation, 
primarily by modulating mRNA decay and miRNA biogenesis (Gherzi et al., 2010).  
mRNA stability varies considerably from one mRNA species to another and plays an 
important role in regulating gene expression levels. Differential mRNA decay rates are 
determined by specific cis-acting elements within the mRNA molecule. KHSRP promotes 
mRNA degradation by AU-Rich Element (ARE)-mediated decay (AMD). The ARE 
elements are found in the 3’untranslated region (3’UTR) of transcripts encoding cytokines, 
transcription factors, cell cycle regulators and proto-oncogenes (Gu et al., 2002; Lin et al., 
2009). Biochemical and functional analyses showed that KHSRP binds to ARE elements 
and then recruits the exosome and other enzymatic complexes required for mRNA 
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degradation (Khabar, 2005; Eberhardt, 2007; Hao & Baltimore, 2009). Extracellular 
signals are able to control mRNA decay rates by targeting KHSRP. At least two signaling 
pathways, the MAPK p38 and Akt/PKB, have been shown to target decay-promoting 
ARE-binding proteins including KHSRP. The analysis of KHSRP primary structure 
revealed the presence of several potential phosphorylation sites, with two of them proved 
to be involved in regulation of KHSRP function in AMD. This finding strongly suggests 
that post-translational modification of KHSRP by phosporylation plays an important role 
in mRNA decay (Briata et al., 2015 and literature in it). 
 Expanding the array of KHSRP functions on RNA metabolism, the protein has been 
proved to promote maturation of select miRNAs from precursors. KHSRP binds to the 
terminal loop (TL) of a cohort of miRNA precursors and interacts with both Drosha and 
Dicer complexes in nuclear and cytoplasmic compartments, respectively. MiRNAs whose 
maturation is favored by KHSRP exert important functions in controlling cell proliferation, 
immune response, metabolic homeostasis, and cell fate determination. For example, 
KHSRP knockdown reduces the expression of mature let-7a and significantly upregulates 
cell proliferation in human bone osteosarcoma epithelial cells U2OS (Trabucchi et al., 
2009). 
We have previously shown that KHSRP plays an important role also in mRNA 
splicing (Puppo et al., 2016). Specifically, KHSRP maintains the epithelial identity of 
mammary gland cells by controlling the alternative splicing of specific pre-mRNAs in 
addition to favoring maturation of select miRNAs. KHSRP belongs to a ribonucleoprotein 
complex that includes hnRNPA1, and the two proteins cooperate in promoting epithelial-
type exon usage of select pre-mRNAs. We showed that TGF-induced EMT in mammary 
gland cells requires silencing of KHSRP while sustained KHSRP expression limits TGF-β-
dependent induction of EMT factors and cell migration. On the contrary, KHSRP 
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knockdown in untreated cells mimics TGF-β-induced EMT. Genome-wide sequencing 
analyses revealed that KHSRP controls (1) the levels of mature miR-192-5p, a microRNA 
that targets a group of EMT factors, and (2) the alternative splicing of a cohort of pre-
mRNAs related to cell adhesion and motility including Cd44 and Fgfr2 (Puppo et al., 
2016).  
In the laboratory where I conducted my thesis, it has been previously described the 
interaction of KHSRP with a lncRNA and its consequences in gene expression regulation. 
KHSRP directly binds to H19 lncRNA in undifferentiated multipotent mesenchymal 
C2C12 cells and this interaction favors KHSRP-mediated decay of labile mRNAs such as 
myogenin. During the early steps of myogenesis, modulation by specific signaling 
pathways induces KHSRP dismissal from H19 and, as a consequence, myogenin mRNA is 
stabilized. Concurrently, KHSRP is repurposed to promote maturation of myogenic 
miRNAs thus favoring myogenic differentiation (Giovarelli et al., 2014). 
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3. AIM OF THE STUDY AND SUMMARY 
 
Studies described above prompted us to search for potential lncRNAs interacting with 
KHSRP and whose expression/function is modulated during EMT.  
We identified a previously uncharacterized mammalian lncRNA expressed in 
epithelial tissues that we termed EPR (after Epithelial Program Regulator). EPR came to 
our attention due to its ability to interact with KHSRP and to counteract TGF-β-induced 
EMT. EPR contains an open reading frame (ORF) that is translated into a small peptide 
localized at epithelial cell junctions. We found that EPR regulates a large set of target 
transcripts independently of the peptide biogenesis. Our studies revealed that EPR interacts 
with chromatin, regulates Cdkn1a gene expression by affecting both its transcription and 
mRNA decay, and controls cell proliferation in both immortalized and transformed 
mammary gland cells as well as in a mouse model of orthotopic transplantation. We 
propose that EPR enables epithelial cells to control proliferation by modulating waves of 
gene expression in response to stimuli. 
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4. RESULTS 
 
4.1 Identification and characterization of EPR, an epithelial cell type- 
enriched lncRNA. 
This study was initiated in an attempt to identify lncRNAs which are able to interact 
with KHSRP and whose expression is regulated by TGF-β in immortalized murine 
mammary gland NMuMG cells. To this end, we leveraged RNA-sequencing (RNA-Seq) 
and anti-KHSRP RNP complexes Immunoprecipitation followed by RNA sequencing 
(RIP-Seq) analyses performed in untreated or TGF-β-treated NMuMG cells. TGF-β 
treatment significantly reduced or increased the levels of 110 and 194 lncRNAs, 
respectively (|log2 fold changes| >2.0, p<0.01; Fig. 1A, left panel) while RIP-Seq analysis 
showed that TGF-β modulates the interaction of KHSRP with 67 lncRNAs (|log2 fold 
changes| >2.0, p<0.01; Fig. 1A, right panel). Among a set of lncRNA candidates of 
potential interest in EMT, we focused on the previously uncharacterized BC030870 
(ENSMUSG00000074300, located on mouse chromosome 8 and transcribed in reverse 
orientation) that we renamed EPR. RIP analysis followed by qRT-PCR as well as band-
shift analysis confirmed that EPR directly interacts with KHSRP (Fig. 1B). TGF-β induced 
a slight increase of EPR levels followed by rapid down-regulation (Fig. 1C) that accounts 
for the reduced interaction between KHSRP and EPR upon a 6 h treatment (Fig. 1A, right 
panel). SMAD complexes are major effectors of TGF-β-dependent transcriptional 
regulation (Budi et al., 2017) and our ChIP-qPCR showed that SMAD3 interacts with EPR 
promoter. SMAD3 binding to EPR promoter is enhanced by a 1 hour TGF-β treatment 
while falls below basal level after 6 hours (Fig. 1D). 
EPR was expressed during embryonic development (Fig.1E) and in epithelial tissues 
of adult mice with a prevalence in the gastro-intestinal tract, lung, kidney and mammary 
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gland (Fig. 1F). EPR was polyadenylated, spliced and almost equally distributed in the 
cytoplasm, nucleoplasm and chromatin of NMuMG cells (Fig. 1G, 1H). LINC01207 (a.k.a. 
SMIM31, located on chromosome 4 and transcribed in forward orientation; hereafter 
indicated as h.EPR) is the human orthologue of EPR and displays superimposable 
epithelial tissue-enhanced expression (as evaluated through the Human BodyMap 2.0 data 
from Illumina; Fig. 1I). Bioinformatics analysis performed on RNA-Seq data derived from 
different subpopulations of normal breast cells isolated by FACS analysis from reduction 
mammoplasty specimens (Pellacani et al., 2016), revealed that h.EPR is expressed 
exclusively in differentiated luminal cells of mammary gland (Fig. 1J). 
In order to investigate the potential role of EPR in TGF-β-induced EMT, we decided 
to counteract its TGF-β-dependent down-regulation by stably overexpressing the lncRNA 
in NMuMG cells (overexpression was 3-12-fold compared to the respective mock cells 
[empty vector-transfected], in different transfectant pools). The levels of transfected EPR 
were not affected by TGF-β treatment (data not shown). EPR overexpression prevented 
TGF-β-dependent morphological and gene expression changes by hindering down-
regulation of epithelial markers (Cdh1, Ocln) and induction of mesenchymal markers (Fn1, 
Fstl1, Zeb2, Adam12) (Fig. 1K, 1L). Strikingly, EPR overexpression changed the levels of 
epithelial and mesenchymal markers and induced a cobblestone-like cell morphology even 
in the absence of TGF-β treatment (Fig 1M, 1N, 1O). As expectable, EPR overexpression 
in NMuMG cells significantly limited their migratory potential both in the absence and in 
the presence of TGF-β treatment (Fig. 1P). Conversely, transient silencing of EPR down-
regulated the mRNA levels of epithelial markers while enhanced the levels of 
mesenchymal markers (Fig. 1Q). Further, transient EPR silencing rescued the gene 
expression changes induced by stable overexpression of the lncRNA (Fig. 1R). A link 
between the expression of h.EPR and EMT-related factors was also observed in human 
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normal breast samples where h.EPR positively correlated with epithelial markers —such as 
CDH1 and OCLN— and negatively correlated with mesenchymal markers such as VIM 
and SNAI1 (Fig. 1S). 
In conclusion, the name EPR that we assigned to lncRNA BC030870 (after Epithelial 
Program Regulator) is consistent with its enriched expression in epithelial cells and with 
the up-regulation of epithelial markers and down-regulation of mesenchymal markers 
induced by its overexpression. 
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FIG.1 EPR displays epithelial expression and antagonizes TGF-β-induced EMT in mammary 
gland cells. 
1A 1B 
1C 1D 
 
1A. RNA-Seq experiments indicated that TGF-βtreatment (24 hours) modulates (|log2 fold  8 changes| >2.0, 
p<0.01) the expression of 304 lncRNAs in NMuMG cells. Arrow points to EPR.  
1B. RIP-Seq analysis revealed that the interaction of KHSRP with 67 lncRNAS is modulated (|log2 fold 
changes| >2.0, p<0.01) by TGF-βtreatment (6 hours). Arrow points to EPR. Total extracts were prepared 
from NMuMG cells and immunoprecipitated as indicated. RNA was purified from immunocomplexes and 
analyzed by qRT-PCR to  quantitate EPR levels. Electrophoretic mobility shift assays (EMSA) performed to 
detect the interaction between highly purified recombinant KHSRP (50–300 nM) with 32P-labeled RNA 
corresponding to nucleotides 246-407 of EPR. A representative autoradiogram is displayed. Arrowhead 
points to the KHSRP-EPR complex.  
1C. Quantitative RT-PCR (qRT-PCR) analysis of EPR in NMuMG cells serum-starved (2% FBS, 16h) and 
either treated with TGF-β (10 ng/ml) for the indicated times or untreated (time 0).  
1D. Chromatin prepared from NMuMG cells serum-starved and either treated with TGF-βfor the indicated 
times or untreated (control) was immunoprecipitated using either normal rabbit IgG (cIgG) or affinity-
purified anti-SMAD3 rabbit polyclonal antibody. The association of SMAD3 with EPR promoter (schematic 
on the top) was quantitated by qPCR using specific primers (indicated as arrowheads). 
The values of qRT-PCR experiments shown are averages (±SEM) of three independent experiments 
performed in triplicate. Statistical significance: *p< 0.01, **p < 0.001 (Student’s t test). 
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1E. qRT-PCR analysis of EPR expression in total RNA extracted from mouse embryos at the indicated 
gestational ages.  
1F. qRT-PCR analysis of EPR in the indicated mouse tissues. 
1G. qPCR analysis of EPR expression evaluated using a set of primers spanning exons 1 and 2 of EPR 
sequence in RNA samples from NMuMG cells retro-transcribed using either random hexamers or oligo-dT 
(as indicated). The position of primers that have been used is indicated in the schematic on the  top.  
1H. NMuMG cells were fractionated and RNA was prepared from cytoplasm, nucleoplasm, and chromatin 
and analyzed by qRT-PCR to quantitate the indicated RNAs. 
The values of qRT-PCR experiments shown are averages (±SEM) of three independent experiments 
performed in triplicate. Statistical significance: *p< 0.01, **p < 0.001 (Student’s t test). 
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1I. The expression levels of h.EPR in multiple human tissue were extracted from the Illumina Human Body 
Map 2.0 data. Data were median centered to distinguish the tissues with high expression of h.EPR. Breast has 
been highlighted in red.  
1J. qRT-PCR analysis of h.EPR in normal human breast cells isolated from reduction mammoplasty 
specimens 
1K. Phase contrast microscopy of either mock or EPR-overexpressing (EPR) NMuMG cells that were serum-
starved and then either treated with TGF-β or untreated for 24 hr. Scale bars: 100 μm. 
1L. qRT-PCR analysis of the indicated transcripts in either mock or EPR-overexpressing NMuMG cells 
serum-starved and either treated with TGF-β (+) for 24h or untreated (-).  
The values of qRT-PCR experiments shown are averages (±SEM) of three independent experiments 
performed in triplicate. Statistical significance: *p< 0.01, **p < 0.001 (Student’s t test). 
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1M.  Phase contrast microscopy of  mock or EPR-overexpressing (EPR) NMuMG cells. Scale bars: 100 μm. 
1N.  Immunoblot analysis of total cell extracts from either mock or EPR-overexpressing  NMuMG cells. The 
indicated antibodies were used. The position of molecular mass markers is indicated on the left. 
Representative gels are shown.  
1O. qRT-PCR analysis of the indicated transcripts in either mock or EPR-overexpressing  NMuMG cells.  
1P.  Scratch wound healing assays. Scratch wounds were introduced into confluent monolayers of either 
mock or EPR-overexpressing NMuMG cells. Cultures were either treated with TGF-β(for 24 hours (+)) or 
left untreated (-). Cultures were photographed and the width of the wound was measured at 0 hr and 24 hr 
after the scratch was made. The percentage of the scratch gap area for each culture condition was plotted.  
Values of qRT-PCR and cell migration assays experiments shown are averages (±SEM) of three independent 
experiments performed in triplicate. Statistical significance: *p< 0.01, **p < 0.001 (Student’s t test).  
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1Q. qRT-PCR analysis of the indicated transcripts in NMuMG cells transiently transfected with either 
control siRNA (siC) or siRNA designed to silence EPR-expression (siEPR). 
1R. qRT-PCR analysis of the indicated transcriptsin either control siRNA (siC) or siEPR-transiently 
transfected (siEPR) NMuMG cells stably overexpressing EPR.  
1S. Pearson correlation analysis between the expression levels of h.EPR and the indicated human transcript 
as calculated by the GEPIA website (http://gepia.cancer-pku.cn) using as input breast normal samples from 
the TCGA dataset and normal mammary gland tissues. Expression levels are plotted as Transcripts per 
million (TPM, log-scale). The p-value of Pearson correlation coefficient (R) and the p-value are presented. 
The values of qRT-PCR shown are averages (±SEM) of three independent experiments performed in 
triplicate. Statistical significance: *p< 0.01, **p < 0.001 (Student’s t test).  
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4.2 EPR encodes a small polypeptide. 
A few recent reports show that certain lncRNAs contain short ORFs that can be 
translated into peptides endowed with regulatory functions (Matsumoto et al., 2017; Huang 
et al., 2017; Andrews & Rothnagel, 2014; Makarewich & Olson, 2017 - for reviews). The 
analysis of EPR sequence revealed the presence of a 213 nucleotide-long ORF potentially 
encoding a 71-amino acid polypeptide that, interestingly, corresponds to the lncRNA 
region that displays the highest identity with the human orthologue (Fig. 2A). The putative 
polypeptide sequence is well conserved among mammalian species and in silico methods 
identified a conserved α-helical transmembrane domain while a predicted second α-helix 
was found in the putative cytosolic domain (Fig. 2B). Importantly, polysome fractionation 
followed by qRT-PCR analysis revealed that EPR localizes to actively translating 
polysomes (Fig 2C). 
To investigate whether EPR ORF is translated, we inserted a FLAG tag at its 3’ end 
and transiently transfected the resulting construct into HEK-293 cells (Fig. 2D, left). As 
shown in Fig. 2D (right), the ORF was translated into a short polypeptide of the expected 
molecular mass. To unambiguously prove the existence of the endogenous small EPR-
encoded peptide (EPRp), the ORF was expressed in bacteria and the resulting peptide was 
purified and utilized as immunogen to generate a rabbit polyclonal antibody. Polyclonal 
anti-EPRp recognized a recombinant polypeptide transiently expressed in HEK-293 cells 
(Fig. 2E) and, most importantly, a ~ 8 KDa polypeptide in mouse gastrointestinal tract 
organs and breast (Fig. 2F). In keeping with EPR downregulation upon TGF-β treatment, 
the expression of the EPRp was downregulated in response to treatment with TGF-β for 24 
h (Fig. 2G). 
In order to identify the molecular partners of EPRp, we performed immunoaffinity 
purification of proteins interacting with EPR in NMuMG cells. Mass spectrometry (MS) 
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analysis of co-immunoprecipitating proteins separated by SDS-PAGE (Fig. 2H) revealed 
an enrichment in junctional and cytoskeletal proteins (Fig. 2I). Co-immunoprecipitation 
experiments confirmed that EPRp interacts with the tight junction proteins TJP1 (ZO-1) 
and CGN (Cingulin), with the tight and adherens junction protein CGNL1 (Paracingulin) 
as well as with the actin-associated proteins CTTN (Cortactin) and MYH9 (epithelial 
myosin-II) (Fig. 2J). 
To establish whether the association of EPRp with junctional proteins reflects its 
subcellular localization, we performed immunofluorescence experiments in NMuMG cells 
stably transfected with either EPRp-FLAG or with a construct in which the second codon 
of the ORF —encoding glutamic acid, E, of EPRp— was mutagenized in order to obtain a 
STOP codon (see also below, EPRSTOPE-FLAG). Specific localization of FLAG signal at 
cell-cell junctions labelled by the junctional marker CGN was detected in cells stably 
expressing EPRp-FLAG (arrows in Fig. 2K) while no junctional FLAG labeling was 
detected in mock-transfected cells or in cells expressing the point mutant version unable to 
produce the peptide. CGN labeling was wavy and discontinuous in mock transfected cells 
and in cells expressing EPRSTOPE-FLAG, whereas it was linear and uninterrupted in cells 
expressing EPRp-FLAG, suggesting that EPRp overexpression promotes epithelial 
junction assembly and reorganization of the junction-associated actin cytoskeleton. A weak 
diffuse cytoplasmic staining observed in NMuMG cells expressing EPRp-FLAG might 
reflect EPRp interaction with cytoskeletal proteins (Fig. 2K). 
On the basis of these results, we conclude that an ORF present in EPR is translated 
into a small peptide that is well conserved among species and that displays a junctional 
localization in epithelial cells. 
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Figure 2. A small peptide (EPRp) originates from EPR and displays junctional localization in 
NMuMG cells.  
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2B                                                     
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2A. Schematic of the exon-intron structure (not in scale) of EPR, a putative ORF is dashed. Percentage of 
human/mouse identity in the putative ORF and in its flanking RNA regions is presented. 
2B. Alignment of the predicted mammalian amino acids sequence encoded by the putative ORF present in 
EPR and in its orthologues. The position of the predicted transmembrane  α-helix is shown as a solid black 
bar while the position of an additional  cytoplasmic α-helix is shown as a solid green bar.  
2C. Left panel. Representative example of polysome profiles obtained from cytoplasmic  lysates of NMuMG 
cells fractionated by sucrose gradients. The relative absorbance of the various fractions is indicated. Four 
pools of fractions corresponding to free RNA + 40S (a),  60S + 80S (b), light polysomes (c), heavy 
polysomes (d) were prepared and processed for RNA extraction and qRT-PCR. Right panel. Relative 
expression of EPR across the four pools of sucrose gradient, cytoplasmic lysate fractions. The average 
relative expression and the standard error of three replicates are plotted.  
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2D. Left, diagram of the FLAG-fusion construct used for transfection (EPRp-FLAG); right, immunoblot 
analysis of total cell extracts from either mock or EPRp-FLAG-transfected HEK-293 cells. 
2E. Immunoblot analysis of total cell extracts from either mock or EPR-transfected HEK-293 cells. Asterisks 
mark nonspecific  immunoreactivity. 
2F. Immunoblot analysis of total extracts from the indicated mouse tissues. Asterisks mark nonspecific 
immunoreactivity.  
2G. Immunoblot analysis of total cell extracts from NMuMG cells serum-starved and either treated with 
TGF-β (+) for 24h or untreated (-);  extracts from EPRp-FLAG-transfected HEK-293 cells (EPRp-FLAG) 
represent a positive control. 
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2H. SDS-PAGE analysis of total cell extracts from either mock or EPRp-FLAG-  overexpressing (EPRp-
FLAG) NMuMG cells immuno-purified using anti-FLAG monoclonal antibody. A representative silver-
stained gel is shown. Asterisks indicate the position of immunoglobulin heavy and light chains. 
2I. List of proteins that specifically interact with  EPRp identified by mass spectrometry after immunoaffinity 
purification and SDS-PAGE  analysis in NMuMG cells stably overexpressing FLAG-tagged EPRp.  
2J. TOP PANEL: Co-immunoprecipitation of FLAG-tagged EPRp and  distinct junctional proteins (as 
indicated) in total extracts from NMuMG cells stably transfected  with EPRp-FLAG.  BOTTOM PANEL: 
Co-immunoprecipitation of FLAG-tagged EPRp and distinct cytoskeletal proteins (as indicated)  in total 
extracts from HEK-293 cells transiently co-transfected with EPRp-FLAG and the  indicated GFP-fused 
proteins. Asterisks mark nonspecific immunoreactivity.  For Immunoblots, the indicated antibodies were 
used; the position of molecular mass markers is indicated on the left and representative gels are shown. 
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2K  Immunofluorescence analysis of either mock or EPRp-FLAG- orEPRpSTOPE-FLAG- stably transfected 
NMuMG cells cultured to confluence, to allow formation of cell-cell junctions. Arrows point to CGN and 
EPRp-FLAG junctional localization.  
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4.3 EPR regulates gene expression in NMuMG cells. 
We set out to investigate the function(s) of EPR in NMuMG cells. First, in order to 
answer the question whether the phenotypic changes that we observed by overexpressing 
EPR were caused by the lncRNA per se, the peptide or both, we performed transcriptome-
wide RNA-Seq analyses in mock cells as well as in NMuMG cells overexpressing either 
EPR or a point-mutant version unable to produce the peptide (EPRSTOPE, for details see 
above and Fig. 3A). Bioinformatics analyses of RNA-Seq data revealed a vast 
rearrangement of the transcriptome as a consequence of both EPR and EPRSTOPE 
overexpression (data not shown). Gene ontology (GO) analysis of RNA-Seq results 
revealed the enrichment of terms related to epithelial morphogenesis, cell motility, cell 
migration, and epithelial cell proliferation among the top regulated categories (data not 
shown). Representative examples of transcripts either up-regulated or down-regulated by 
both EPR and EPRSTOPE are shown in Fig. 3B). In keeping with the sequence 
conservation between EPR and h.EPR, the overexpression of the human lncRNA in murine 
NMuMG cells yielded gene expression changes superimposable to those obtained by 
overexpressing the murine lncRNA (Fig. 3C). 
Interestingly, overexpression of either EPR or EPRSTOPE caused largely overlapping 
gene expression changes when compared to mock cells (Fig. 3D, left panel). When we 
directly compared gene expression changes induced by EPR or EPRSTOPE by applying 
stringent statistical criteria, we noticed that only a relatively small group of genes 
displayed expression changes dependent on the presence of EPR (Fig. 3D, right panel). 
The analysis of three independent NMuMG transfectant pools overexpressing EPRSTOPE, 
followed by qRT-PCR-based validation, allowed us to further restrict the number of 
transcripts whose levels are affected by EPR overexpression in a peptide-dependent way 
(Fig. 3E). These include transcripts encoding a calcium-dependent cell adhesion protein 
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(Pcdh19), two ion transporters (Slc9a2, Scl39a4), a cytokine receptor (Fgfr2) as well as a 
modulator of membrane transport and actin dynamics (Anxa6). Further, analysis of an 
additional EPR mutant (referred to as EPRSTOPM in which the start codon has been 
mutagenized to a STOP codon, see below) confirmed the restricted number of gene 
expression changes that can be ascribed to the peptide translation (Fig. 3F). 
Considering the emerging evidence that some lncRNAs act locally (in cis) to regulate 
the expression of nearby genes, we investigated this possibility and RNA-Seq analysis 
revealed that the expression levels of genes proximal to EPR (Palld, Cpe, Sc4mol, Klhl2, 
Tmem192, Tma16, Naf16, Nat2 and Pssd, localized over 8 MB of chromosome 8) are 
unaffected by the almost complete EPR down-regulation that occurs in NMuMG cells 
treated with TGF-β for 24 hours (Paola Briata et al., unpublished observation). 
 Altogether, transcriptome-wide analyses showed a EPR-dependent wide 
rearrangement of the transcriptome in NMuMG cells with relatively restricted effects on 
gene expression attributable to the peptide. Thus, we decided to focus our further studies 
on the peptide-independent functions of EPR. 
  
43 
 
  
Figure 3. EPR overexpression reshapes NMuMG cells transcriptome independently of 
EPRp translation.  
 
3A 
3B 
3C 
 
3A. Schematic of the point mutation that was introduced in the second codon of the EPR ORF to generate 
the EPRSTOPE construct (left panel). HEK-293 cells were transiently transfected with either EPR or 
EPRSTOPE constructs and the translation of EPR was assessed by immunoblotting (right panel).  
3B. qRT-PCR analysis of the indicated transcripts in either mock, EPR- or EPRSTOPE- expressing 
NMuMG cells.  Immunoblot analysis of total cell extracts from either mock, EPR- or EPRSTOPE- 
overexpressing NMuMG cells.  
3C. qRT-PCR analysis of the indicated transcripts in either mock or human EPR (h.EPR) overexpressing 
NMuMG cells The values of qRT-PCR experiments shown are averages (±SEM) of three independent 
experiments performed in triplicate. Statistical significance: *p< 0.01, **p < 0.001 (Student’s t test). For 
Immunoblots, the indicated antibodies were used; the position of molecular mass markers is indicated on 
the left and representative gels are shown. 
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3D. Left panel, TopTable Venn diagram of the limma one-factor contrast analysis showing the overlap 
between transcripts either upregulated (numbers in red) or downregulated (numbers in blue) in NMuMG cells 
stably over-expressing either EPR or EPRSTOPE compared with mock cells. Only transcripts displaying 
|log2 fold expression difference| >2.5 (p<0.0001) were included in the graph and in further comparisons. 
Right panel, Pie diagram showing the percentage of gene expression changes common to NMuMG cells 
overexpressing EPR and EPRSTOPE as well as the percentage of changes that can be specifically attributed 
to the EPR translation (limma one-factor interaction contrast). 
3E. qRT-PCR analysis of the indicated transcripts in either mock, EPR- or EPRSTOPE- overexpressing cells. 
3F. Immunoblot analysis of HEK-293 cells transiently transfected with either the empty vector, EPR or 
EPRSTOPM (right panel). qRT-PCR analysis of the indicated transcripts in either mock, EPR or 
EPRSTOPM- overexpressing NMuMG cells (left panel). The values of qRT-PCR experiments shown are 
averages (±SEM) of three independent experiments performed in triplicate. Statistical significance: *p< 
0.01,**p < 0.001 (Student’s t test). 
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4.4 EPR regulates Cdkn1a gene expression and cell proliferation. 
 Among the GO terms significantly enriched by both EPR and EPRSTOPE we 
identified the category “regulation of epithelial cell proliferation”. Indeed, both EPR and 
EPRSTOPE overexpression significantly affected the levels of a group of transcripts 
belonging to this category including the cyclin-dependent kinase inhibitor Cdkn1a (a.k.a. 
p21WAF1/Cip1) (Fig. 4A). Immunoblots presented in Fig. 4B show that overexpression of 
either EPR or EPRSTOPE or EPRSTOPM strongly enhanced CDKN1A levels. 
Conversely, EPR silencing strongly reduced CDKN1A expression (Fig. 4C). As 
expectable, CDKN1A levels were enhanced by overexpression of the human orthologue of 
EPR (Fig. 4D). Most important, we found that overexpression of either EPR or 
EPRSTOPE as well as of h.EPR strongly reduces cell proliferation rate in NMuMG cells 
(Fig. 4E).  
Similar results were obtained by analyzing both cell proliferation and gene expression 
changes in different NMuMG cell pools transfected with EPR cloned in various vector 
backbones (data not shown). Cell cycle analysis demonstrated a relevant increment of cells 
arrested in G1 in the case of NMuMG cells transfected with either EPR or EPRSTOPE in 
comparison to mock cells (Fig. 4F). To exclude the possibility that gene expression 
changes that we prevously observed (Fig. 3B) might be dependent on the EPR-induced G1 
arrest, we sorted cells in the G1 phase and analyzed gene expression changes by qRT-PCR. 
Data presented in Fig. 4G indicate that both EPR and EPRSTOPE induced gene expression 
changes in G1-enriched cells are superimposable to those observed in the total cell 
population (compare Fig. 4G with Fig. 3B). 
Together, these results provide evidence that modulation of EPR levels regulates 
Cdkn1a gene expression and affects cell proliferation in NMuMG cells. Given the role of 
CDKN1A in promoting cell cycle arrest in response to many stimuli —including TGF-β 
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(Abbas & Dutta, 2016)—, we decided to focus our further mechanistic studies on the role 
of EPR in TGF-β-dependent regulation of Cdkn1a gene expression. 
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Fig 4. EPR regulates Cdkn1a gene expression and cell proliferation. 
4A 4B 
4C 4D 
 
4A. qRT-PCR analysis of the indicated transcripts in either mock, EPR or EPRSTOPE overexpressing 
NMuMG cells. 
4B. Immunoblot analysis of total cell extracts from mock, EPR-, EPRSTOPE- or EPRSTOPM-
overexpressing NMuMG cells.  
4C . qRT-PCR analysis of Cdkn1a mRNA levels in control siRNA (siC) or siEPR-transfected NMuMG cells 
(upper panel). Immunoblot analysis of total cell extracts from control siRNA (siC) or siEPR-transfected 
NMuMG cells (lower panel).  
4D. qRT-PCR of Cdkn1a mRNA levels in either mock or human EPR (h.EPR)-overexpressing NMuMG cells 
(top panel). Immunoblot analysis of mock or human EPR (h.EPR) overexpressing NMuMG cells (bottom 
panel).  Values of qRT-PCR are averages (±SEM) of three independent experiments performed in triplicate. 
Statistical significance:*p<0.01,**p<0.001 (Student’s t test).  
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4E 4F 
4G 
 
4E. Left:Proliferation analysis (OperettaCLS High-Content Analysis System) of mock, EPR- or 
EPRSTOPE- overexpressing NMuMG cells. Right: cell proliferation analysis (analyzed by Crystal violet 
staining) of either mock or human EPR (h.EPR) -overexpressing NMuMG cells.  
4F. Cell cycle distribution in cultures grown at similar density (near 90% confluence). Cell cycle was 
analyzed by flow cytometry after double staining with EdU and Propidium Iodide of mock, EPR- or 
EPRSTOPE- overexpressing NMuMG cells. Bars plot the relative proportion of cells in G1, S, and G2 
phases for each cell line. 
4G. G1 cell sorting of mock, EPR or EPRSTOPE-overexpressing NMuMG cells. Cells were stained by 
Hoechst 33342 and processed using a BD Aria II cytometer. The pre-sorting cell cycle profile (top left), 
gating (green area in the dot plot, bottom left), and purity checked by post-sorting sample re-run (center 
panels) are shown for one replicate of the mock sample; SSC-A is for side scatter area. qRT-PCR analysis of 
the indicated transcripts in either mock, EPR or EPRSTOPE-overexpressing cells sorted in the G1 phase of 
the cell cycle (right panels). Values of qRT-PCR and cell proliferation experiments shown are averages 
(±SEM) of three independent experiments performed in triplicate.. Statistical significance: **p < 0.001 
(Student’s t test). For Immunoblots, the indicated antibodies were used; the position of molecular mass 
markers is indicated on the left and representative gels are shown. 
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4.5 EPR regulates TGF-β-dependent Cdkn1a gene expression at different 
levels. 
Analysis of newly synthesized transcripts revealed that EPR overexpression strongly 
enhances Cdkn1a transcription (Fig. 5A) and the kinetic analysis of mRNA decay 
indicated that EPR overexpression induces also a significant stabilization of Cdkn1a 
mRNA (Fig. 5B). 
TGF-β signaling promotes tissue growth and morphogenesis during embryonic 
development while, as tissues mature, many cell types gain the ability to respond to TGF-β 
with growth arrest that is primarily due to imbalance of G1 events (Siegel & Massagué, 
2003). As similarly reported in other cell types (Seoane et al., 2004; Pardali et al., 2005), 
treatment of NMuMG cells with TGF-β for 1 hour caused a rapid induction of Cdkn1a 
gene expression that was followed by return to baseline levels after 6 hours (Fig. 5C). The 
observation that Cdkn1a return to baseline levels matches EPR downregulation (Fig. 5C) 
and that EPR overexpression strongly enhances Cdkn1a levels, prompted us to hypothesize 
a role for EPR in the TGF-β-dependent modulation of Cdkn1a gene expression. Our ChIP-
qPCR assays showed that TGF-β treatment for 1 hour stimulates the binding of SMAD3 to 
Cdkn1a promoter that returns to basal levels after 6 hours (Fig. 5D, see also Seoane et al., 
2004). TGF-β-dependent control of Cdkn1a mRNA decay was never investigated in detail 
but, considering that cells often achieve rapid changes of gene expression by integrating 
gene transcription control with regulated mRNA decay (Komili & Silver, 2008; Braun & 
Young, 2014), we addressed the possibility that TGF-β could affect Cdkn1a mRNA decay. 
Fig. 5E showed that Cdkn1a mRNA stability is unaffected by 1 hour of TGF-β treatment 
(upper panel) but is reduced when the treatment is prolonged up to 6 hours (lower panel). 
Thus, the TGF-β-dependent rapid fluctuations of Cdkn1a expression depend on the 
regulation of both transcription and mRNA decay in NMuMG cells. 
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Our hypothesis that EPR plays a role in the regulation of TGF-β-dependent CDKN1A 
expression was supported by the evidence that EPR silencing abrogates Cdkn1a mRNA 
induction upon TGF-β treatment for 1 hour (Fig. 5F) while its overexpression enhances 
Cdkn1a levels and blunts its rapid modulation by TGF-β (Fig. 5G). 
Together, our results indicate that EPR plays a dual role in TGF-β-dependent Cdkn1a 
gene expression control. 
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Figure 5. Dual regulation of Cdkn1a gene expression by EPR. 
5A 5B 
5C 5D 
 
5A. qRT-PCR analysis of either total (left) or nascent (right) Cdkn1a transcript in either mock, EPR- or 
EPRSTOPE- overexpressing NMuMG cells.  
5B. Either mock, EPR- or EPRSTOPE- overexpressing NMuMG cells were treated with 100 μM 5,6-
Dichlorobenzimidazole 1-β-D-ribofuranoside (DRB) for different times (as indicated). Cdkn1a gene 
expression was analyzed by qRT-PCR.  
5C. qRT-PCR analysis of Cdkn1a (black line) and EPR (red line) in NMuMG cells serum-starved (2% FBS, 
16h) and either treated with TGF-β (10 ng/ml) for the indicated times or untreated (time 0).  
5D. Chromatin prepared from NMuMG cells serum-starved and either treated with TGF-β for the indicated 
times or untreated (control) was immunoprecipitated using either normal rabbit IgG (cIgG) or affinity-
purified anti-SMAD3 rabbit polyclonal antibody. The association of SMAD3 with Cdkn1a promoter 
(schematic on the top) was quantitated by qPCR using specific primers (indicated as arrowheads). 
The values of both qRT-PCR and qPCR experiments shown are averages (±SEM) of three independent 
experiments performed in triplicate. Statistical significance: *p< 0.01, **p < 0.001 (Student’s t test). 
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5E 5F 
5G 
 
5E. NMuMG cells were serum-starved (2% FBS, 16h) and either treated with TGF-β (10 ng/ml) for either 1 
hour (top panel) or 6 hours (bottom panel) or left untreated (control in both panels). Subsequently, cells were 
treated with 100 μM DRB for the indicated times and total RNA was isolated and analyzed by qRT-PCR to 
quantitate Cdkn1a mRNA levels. Please note the slight, reproducible difference in the decay kinetic of 
Cdkn1a mRNA between non-transfected and mock-transfected NMuMG cells.  
5F. qRT-PCR analysis of Cdkn1a in NMuMG cells transiently transfected with either control siRNA (siC) or 
siRNA designed to silence EPR-expression (siEPR), serum-starved (2% FBS, 16h) and then either treated 
with TGF-β (10 ng/ml) for 1 hour (+) or left untreated (-).  
5G. qRT-PCR analysis of Cdkn1a expression in either mock (blue line) or EPR overexpressing (red line) 
NMuMG cells serum-starved (2% FBS, 16h) and either treated with TGF-β (10 ng/ml) for the indicated times 
or left untreated (time 0). Please note the logarithmic scale of the Y axis. The values of qRT-PCR 
experiments shown are averages (±SEM) of three independent experiments performed in triplicate. Statistical 
significance: *p< 0.01, **p < 0.001 (Student’s t test). 
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4.6 EPR affects both SMAD3-dependent Cdkn1a gene transcription and 
KHSRP-regulated mRNA decay. 
We investigated the molecular mechanism(s) by which EPR regulates Cdkn1a gene 
transcription. The evidence of enhanced RNA-Pol II occupancy and reduced presence of 
the H3K27me3 repressive mark at the Cdkn1a promoter in EPR-overexpressing cells (Fig. 
6A) together with our finding that EPR is present in the chromatin fraction (see Fig. 1H), 
prompted us to explore the possibility that EPR affects Cdkn1a transcription through direct 
interaction with its promoter region. Chromatin Isolation by RNA Purification (ChIRP)-
Seq experiments (Paola Briata., Gabriele Bucci., Ettore Zapparoli et al., unpublished 
observation) as well as ChIRP-qPCR experiments revealed the direct interaction of EPR 
with Cdkn1a promoter (Fig. 6B). The interaction of EPR with Cdkn1a promoter is not 
significantly affected by a 1 hour TGF-β treatment (Fig. 6C). 
RIP experiments showed that SMAD3 interacts with EPR and the interaction is 
enhanced by treatment with TGF-β for 1 hour (6D). In keeping with growing evidence 
suggesting that the interaction between lncRNAs and specific transcription factors can 
affect gene expression (Long et al., 2017; Li et al., 2017), ChIP-qPCR experiments showed 
that EPR overexpression enhances SMAD3-Cdkn1a promoter association and abrogates its 
modulation by TGF-β thus preventing the dismissal of SMAD3 from the Cdkn1a promoter 
upon TGF-β treatment for 6 hours (Fig. 6E). These effects are reproduced by 
overexpression of EPRSTOPE (Fig. 6E). Notably, EPR overexpression favored SMAD3-
Cdkn1a promoter interaction not only in TGF-β-treated NMuMG cells but also in untreated 
cells (Fig. 6E). Although SMAD proteins rapidly accumulates into nuclei upon TGF-β 
treatment (Reguly & Wrana, 2003) a certain amount of SMAD3 is present in the nuclei of 
untreated cells (Schmierer & Hill, 2005; Fig. 6F) thus suggesting that EPR overexpression 
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favors the recruitment of SMAD3 molecules already present in the nucleus of cells not 
treated with TGF-β. 
 In keeping with results shown in Fig. 5B, we found that EPR overexpression 
prevents Cdkn1a mRNA destabilization induced by a treatment with TGF-β for 6 hours 
(Fig. 6G). Our original observation that EPR interacts with KHSRP, a factor able to 
promote rapid decay of select labile mRNAs in many cell types (Briata et al., 2013), 
prompted us to explore whether KHSRP regulates Cdkn1a mRNA decay in NMuMG cells. 
Indeed, KHSRP silencing induced Cdkn1a mRNA accumulation and prevented its rapid 
degradation (Fig. 6H, 6I) while transient KHSRP overexpression in NMuMG cells stably 
expressing EPR promoted Cdkn1a mRNA destabilization (Fig. 6H lower panel). KHSRP is 
predominantly nuclear in NMuMG cells (Puppo et al., 2016) and we found that mature 
Cdkn1a mRNA is abundant in nuclear fractions of these cells where it undergoes rapid 
decay and is stabilized by EPR overexpression as measured by two independent techniques 
(6J). These findings suggested that EPR might interfere with the ability of KHSRP to 
interact with Cdkn1a mRNA. RIP experiments presented in Fig.6K show that KHSRP 
association with Cdkn1a mRNA was strongly reduced by EPR and EPRSTOPE 
overexpression. Based on these results, we investigated whether EPR down-regulation, that 
is physiologically obtained by TGF-β-treatment, affects the interaction of KHSRP with 
Cdkn1a mRNA. RIP analyses indicated that upon TGF-β treatment (6 hours) KHSRP-EPR 
is abrogated while KHSRP interaction with Cdkn1a mRNA is increased (Fig. 6L). 
 Altogether, these results suggest that EPR controls Cdkn1a expression by 
sustaining its transcription and impairing its mRNA decay in response to TGF-β. 
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Figure 6. EPR associates with Cdkn1a promoter and affects both SMAD3-dependent 
Cdkn1a gene transcription and KHSRP-regulated Cdkn1a mRNA decay. 
6A 6B 
6C 6D 
6A.Top panel:chromatin prepared from either mock or EPR-overexpressing NMuMG cells was 
immunoprecipitated using either normal mouse IgG (cIgG) or mouse monoclonal anti- PolII antibody. The 
association of PolII with Cdkn1a promoter was verified by qPCR using specific primers. Bottom panel, 
chromatin prepared from either mock or EPR-overexpressing NMuMG cells was immunoprecipitated using 
either normal rabbit IgG (cIgG) or affinity purified rabbit anti-H3K27me3 antibody. The association of 
H3K27me3 with Cdkn1a promoter was verified by qPCR using specific primers. 
6B. ChIRP analyses performed using NMuMG cell lysates and either even or odd EPR probe sets. Top panel 
is a schematic of EPR and shows the location of biotinylated odd (black lines) and even (red lines) tiling 
oligonucleotides used for ChIRP. Both input and purified DNA were analyzed by qPCR using primers 
designed on Rpl32 (negative control) or Cdkn1a promoters. Values are averages (±SEM) of three 
independent experiments performed in triplicate. 
6C. NMuMG cells were serum-starved (2% FBS, 16h) and treated with TGF-β(10 ng/ml) for 1 hour (+) or 
left untreated (-). ChIRP analyses was performed using cell lysates and either even or odd EPR probe sets. 
Both input and purified DNA were analyzed by qPCR using primers designed on Rpl32 (neg. control) or 
Cdkn1a promoters.Values are averages (±SEM) of three independent experiments performed in triplicate.  
6D. NMuMG cells were serum-starved (2% FBS, 16h) and treated with TGF-β (10 ng/ml) for 1 hour (+) or 
left untreated (-). Total extracts were prepared and immunoprecipitated as indicated. RNA was purified from 
immunocomplexes and analyzed by qRT-PCR to quantitate EPR levels.  
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6F 6G 
 
6E. Chromatin was prepared from either mock, EPR- or EPRSTOPE- overexpressing NMuMG cells serum-
starved (2% FBS, 16h) and either treated with TGF-β (10 ng/ml) for the indicated times or left untreated 
(control). Chromatin was immunoprecipitated using either normal rabbit IgG (cIgG) or affinity-purified anti-
SMAD3 rabbit polyclonal antibody. The association of SMAD3 with Cdkn1a promoter was verified by 
qPCR using specific primers.  
6F. Immunoblot analysis of either cytoplasmic (c) or nuclear (n) cell extracts from either mock or EPR  
overexpressing  NMuMG cells. The indicated antibodies were used; the position of molecular mass markers 
is indicated on the left and representative gels are shown.   
6G. Either mock or EPR-overexpressing NMuMG cells were serum-starved (2% FBS, 16h) and either treated 
with TGF-β (10 ng/ml) for 6 hours or left untreated (control). Subsequently, cells were treated with 100 μM 
DRB for the indicated times and total RNA was isolated and analyzed by qRT-PCR to quantitate Cdkn1a 
mRNA levels. Values of qRT-PCR experiments are averages (±SEM) of three independent experiments in 
triplicate. Statistical significance: *p< 0.01, **p  137 < 0.001 (Student’s t test). 
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6H 6I 
6J 
 
6H.  Top panel, mock or shKHSRP NMuMG cells were treated with 100 μM DRB. Total RNA was isolated 
at different times and analyzed by qRT-PCR to quantitate Cdkn1a mRNA levels. Bottom panel, NMuMG 
cells stably overexpressing EPR were infected with either control (AdNull) or KHSRP-expressing 
(AdKHSRP) adenoviral vectors for 24 hours and then treated with 100 μM DRB. Total RNA was isolated at 
different times (as indicated) and analyzed by qRT-PCR to quantitate Cdkn1a mRNA levels.  
6I. qRT-PCR analysis of total RNA isolated from either mock or shKHSRP NMuMG cells. Please note that 
NMuMG mock cells used for these experiments differ from those presented throughout this report and have 
been described in Puppo et al. (2016). 
6J. Left: qRT-PCR analysis of polyadenylated and spliced Cdkn1a mRNA isolated from either cytoplasmic 
(cyto) or nuclear (nuc) extracts of NMuMG cells. Center: mock or EPR overexpressing cells were treated 
with 100μM DRB. Nuclear and cytoplasmic RNAs were isolated at different times an analyzed by qRT-PCR 
to quantitate polyadenylated and spliced Cdkn1a mRNA levels.. Right: Run-off  analysis of EU-labeled 
nuclear RNA prepared fromeither mock-transfected (mock) or EPR- overexpressing (EPR) NMuMG cells 
(chase time 0 and 60 minutes). Values of qRT-PCR and qPCR experiments are averages (±SEM) of three 
independent experiments performed in triplicate. Statistical significance:*p< 0.01,**p 137 < 0.001 (Student’s 
t test).  
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6K 6L 
 
6K. Total extracts from either mock, EPR- or EPRSTOPE- overexpressing NMuMG cells were 
immunoprecipitated as indicated. RNA was purified from immunocomplexes and analyzed by qRT-PCR to 
quantitate Cdkn1a mRNA levels.  
6L. Total extracts were prepared from NMuMG cells serum-starved (2% FBS, 16h) and either treated with 
TGF-β (10 ng/ml) for the indicated times or left untreated (time 0) and immunoprecipitated as indicated. 
RNA was purified from immunocomplexes and analyzed by qRT-PCR to quantitate EPR and Cdkn1a mRNA 
levels. The values of both qRT-PCR experiments shown are averages (±SEM) of three independent 
experiments performed in triplicate. Statistical significance: *p< 0.01, **p < 0.001 (Student’s t test). 
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4.7 EPR overexpression reduces breast cancer cell proliferation. 
We investigated EPR in murine breast cancer cell lines and observed that its 
expression is severely reduced when compared with immortalized NMuMG cells (Fig. 
7A). Similarly, the expression of h.EPR was below detection levels in highly aggressive 
human breast cancer cell lines (Matteo J. Marzi and Francesco Nicassio, unpublished 
observation). H.EPR could be detected in about 75% of breast cancer primary samples 
(780/1043 cases from The Cancer Genome Atlas (TCGA) database (Cancer Genome Atlas 
Network, 2012) (7B left) and, according to PAM50 molecular subtype classification, it was 
more expressed in Luminal A and Her2 tumors while it was almost absent in Basal-like 
tumors, the most frequent subtype of triple negative breast cancers (Bianchini et al., 2016) 
(Fig. 7B right). 
Based on these observations, we decided to express either EPR or EPRSTOPE in 
triple-negative mesenchymal-like breast cancer cells, such as murine 4T1 and human 
MDA-MB-231 cell lines, respectively. 
EPR and EPRSTOPE overexpression in 4T1 cells (Fig. 7C) resulted in a strong 
induction of Cdkn1a gene expression (Fig. 7D, 7E left panel) as well as in a significant 
reduction of clonogenic potential, cell proliferation, and anchorage-independent cell 
growth (Fig 7E right panel, 7F). EPR overexpression in 4T1 cells also down-regulated 
mesenchymal factors such as Cdh2 and Adam12 (Fig. 7G). Very similar results were 
observed by overexpressing either human or murine EPR in human MDA-MB-231 cells 
(Fig. 7H, 7I). 
Finally, to interrogate the activity of EPR on cell proliferation control in vivo, we 
orthotopically injected either mock or EPR-expressing 4T1 cells into syngenic BALB/c 
mice. In concordance with our observations in cultured cells, EPR expression resulted in a 
remarkable reduction of tumor volume after 10 days (Fig. 7J, left panel). A significant 
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reduction of the tumor mass was still evident and statistically significant also at two weeks 
after the transplant when mice were sacrificed (Fig. 7J right panel; Fig. 7K). 
Altogether, our results indicate that EPR overexpression modulates cell proliferation 
and epithelial/mesenchymal markers levels in breast cancer cells and restrains cell 
proliferation in transplanted mice. 
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Figure 7. Anti-proliferative effect of EPR when expressed in transformed mammary 
gland cells. 
7A 
7B 
 
7A. The expression of EPR was quantitated by qRT-PCR analysis in the indicated cell types. values of qRT-
PCR experiments shown are averages (±SEM) of three independent experiments performed in triplicate. 
Statistical significance: **p < 0.001 (Student’s t test). 
7B. Left Panel: distribution of h.EPR in the TCGA Breast Cancer (BRCA) dataset. Right panel:Box-plot 
shows the expression of h.EPR in the TCGA Breast Cancer (BRCA) dataset annotated according to PAM50 
molecular subtype classification. The number of samples in each subtype is also presented. Asterisks mark 
significant values (Wilcoxon’s test; * p<0.05, *** p<0.001).  
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7C 
 
 
7D 
 
 
7E 
 
 
7C. qRT-PCR analysis of EPR levels in mock, EPR or EPRSTOPE-overexpressing 4T1 cells. 
7D. qRT-PCR analysis of Cdkn1a mRNA levels in either mock, EPR- or EPRSTOPE- overexpressing 4T1 
cells (left panel).  
7E. Immunoblot analysis of either mock, EPR- or EPRSTOPE- overexpressing 4T1 cells (left panel). 
Right panel: Either mock, EPR- or EPRSTOPE- overexpressing 4T1 cells were seeded at low density in 6-
well plates, and colony-formation assays were performed after 4 days. A representative (of four 
independent) plate is shown. The values of colony number quantitation are averages (±SEM) of four 
independent experiments performed in duplicate. Statistical significance: ***p < 0.00001 (Student’s t test). 
The values of qRT-PCR experiments shown are averages (±SEM) of three independent experiments 
performed in triplicate. Statistical significance: **p < 0.001 (Student’s t test).  
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7F 
7G 
 
7F. Left: Cell proliferation analysis (quantitated using Crystal violet staining) of either mock, EPR- or 
EPRSTOPE- overexpressing 4T1 cells.  Right: Either mock, EPR- or EPRSTOPE- overexpressing 4T1 cells 
were cultured in soft agar for 21 days and phase contrast micrographs were taken at 10 X magnification. The 
values are averages (±SEM) of four independent experiments performed in triplicate. Statistical significance: 
***p < 0.00001 (Student’s t test).  
7G. qRT-PCR analysis of the indicated transcripts in either mock-transfected (mock) or EPR-overexpressing 
(EPR) 4T1 cells. The values of qRT-PCR experiments shown are averages (±SEM) of three independent 
experiments performed in triplicate. Statistical significance: **p < 0.001 (Student’s t test). 
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7H  
7I 
 
7H. Left panel: qRT-PCR analysis of CDKN1A mRNA levels in either mock, EPR- or EPRSTOPE- 
overexpressing MDA-MB-231 cells.  Right panel: Cell proliferation analysis (quantitated using Crystal violet 
staining) of either mock or h.EPR-overexpressing MDA-MB-231 cells.  
7I. Left: Cell proliferation analysis (using Crystal violet staining) of either mock or EPR-overexpressing 
MDA-MB-231 cells. Center: qRT-PCR analysis of the indicated transcripts in either mock-transfected 
(mock) or human EPR-overexpressing (h.EPR) MDA-MB-231 cells. Right: Either mock or h.EPR-
overexpressing MDA-MB-231 cells were seeded at low density in 6-well plates and colony-formation assays 
were performed after 6 days. A representative (of three independent) plate is shown. The values of qRT-PCR 
experiments shown are averages (±SEM) of three independent experiments performed in triplicate. Statistical 
significance: **p < 0.001 (Student’s t test). The values of cell proliferation experiment are averages (±SEM) 
of three independent experiments performed in triplicate. Statistical significance: *p< 0.01, **p < 0.001 
(Student’s t test). 
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7J 7K 
 
7J. Tumor volume (n = 6 tumors/group) was measured by digital caliper assessment ten days after injection 
of either mock or EPR-expressing 4T1 cells in BALB/c mice. Box plot analysis of tumor volume is shown 
(left panel). Data were analyzed in R version 3.4.3, using the statistic method Wilcoxon Unpaired Test as 
implemented in `stat_compare_means` in ‘ggplot 2.2.1’. Images of the tumors at the end of the experiment, 
two weeks after injection (right panel). 
7K. Tumors (n = 6 tumors/group) were removed and weighted at the end of the experiment (two weeks). Box 
plot analysis of tumor weight is shown. Data were analyzed in R version 3.4.3, using the statistic method 
Wilcoxon Unpaired Test as implemented in `stat_compare_means` in ‘ggplot 2.2.1’. 
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5. DISCUSSION 
 
In this thesis I report on the initial functional characterization of the long intergenic 
non-coding RNA EPR well conserved among mammalian species and expressed in select 
epithelial tissues including differentiated luminal cells of human breast. The levels of EPR 
are rapidly downregulated by TGF-β/SMAD signaling in immortalized mammary gland 
cells and its sustained expression largely reshapes the transcriptome inducing epithelial 
traits while preventing the acquisition of mesenchymal markers upon TGF-β treatment. 
Remarkably, EPR overexpression enhances the levels of the cyclin-dependent kinase 
inhibitor CDKN1A and strongly reduces cell proliferation in both immortalized and 
transformed mammary gland cells as well as in transplanted mice. 
 EPR is almost equally distributed in chromatin, nucleoplasm and cytoplasm of 
epithelial cells and the cytoplasmic component associates with polysomes where a small 
peptide (EPRp) is translated. EPRp interaction with a variety of cytoskeletal and junctional 
proteins accounts for its junctional localization. However, the analysis of the phenotype 
that we observed in cells overexpressing EPR mutants unable to originate the peptide 
clearly indicates that the vast majority of gene expression changes that we describe here 
are independent of the peptide biogenesis. 
In this project, I investigated how the lncRNA molecule per se controls gene 
expression and I focused our studies on the EPR-dependent regulation of CDKN1A that 
functions as both a sensor and an effector of multiple anti-proliferative signals and 
promotes cell cycle arrest in response to TGF-β (Abbas & Dutta, 2009). In NMuMG cells, 
TGF-β induces an early wave of Cdkn1a expression due, in part, to an increased SMAD 
complex-dependent gene transcription while a prolonged treatment causes the return of 
Cdkn1a levels to the baseline. Our data suggest that Cdkn1a promoter-bound EPR recruits 
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SMAD3 —that accumulate into the nucleus upon TGF-β treatment for 1 hour— to induce 
rapid gene transcription. In parallel, EPR interacts with KHSRP limiting its association 
with Cdkn1a mRNA and this results in its stabilization. I propose that EPR down-
regulation upon 6 hours of TGF-β treatment causes SMAD3 dismissal from Cdkn1a 
promoter that results in a return of Cdkn1a transcription to basal levels and, in parallel, 
enables KHSRP to destabilize the Cdkn1a transcript. Thus, EPR-regulated molecular 
events shape the rapid wave of Cdkn1a expression in response to TGF-β. The evidence that 
in cells overexpressing EPR CDKN1A is abundant even in the absence of TGF-β treatment 
can be explained by EPR ability to recruit SMAD3 molecules already present in cell nuclei 
to Cdkn1a promoter region as well as to prevent KHSRP-induced Cdkn1 mRNA 
degradation. 
Data presented in this thesis indicate that EPR couples Cdkn1a transcriptional 
regulation with mRNA decay control. Indeed, the integration of transcription and mRNA 
decay provides a kinetic boost to a series of processes that would be otherwise slower and 
less efficient. Our data strengthen the idea that coupling transcription to mRNA decay 
enables cells to rapidly modulate waves of gene expression in response to a variety of 
stimuli thus achieving optimal mRNA homeostasis (Komili & Silver, 2008; Braun & 
Young, 2014). 
 Since the decay of mature mRNAs is generally thought to occur in the cytoplasm, 
our finding that spliced and polyadenylated Cdkn1a mRNA is abundant in the nucleus of 
NMuMG cells, where it undergoes regulated decay, might be somehow surprising. 
However, the possibility that mature mRNAs accumulate in the nuclei of mammalian cells 
has been described (Gondran et al., 1999; Bahar et al., 2015) and a previous report has 
suggested that Cdkn1a mRNA undergoes degradation by the nuclear exosome in 
mammalian cells (Singer et al., 2012). Further, a report about mature RNA degradation 
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controlled by nuclear histone acetyltransferases and deacetylases provocatively suggested 
the possibility that mRNA degradation pathways might operate also in the nucleus (Sharma 
et al., 2016). 
The TGF-β cytostatic program in epithelial cells involves, among other molecular 
events, the induction of Cdkn1a and Cdkn2b but cancer cells utilize any opportunity to 
circumvent TGF-β ability to inhibit cell proliferation. Inactivating mutations in the TGF-β 
Type-II receptors and SMAD4 have been described in tumors even though cancer cells can 
lose the cytostatic responsiveness due to defects downstream to SMAD factors. Under 
these conditions, transformed cells may exploit other functional properties of TGF-β 
turning this pathway into a proliferative signal. TGF-β phenotypic switch from a tumor 
suppressor to a tumor inducer is known as the “TGF-β paradox” and represents an 
unanswered question concerning its physio-pathological role (Principe et al., 2014). I 
hypothesize that the absence of EPR/h.EPR, that occurs in breast cancer cell lines and in 
certain breast cancers, may contribute to the loss of TGF-β ability to restrain cell 
proliferation while may enable the cytokine to sustain their carcinogenic potential. 
The notion that lncRNAs are devoid of coding potential has been recently challenged 
by reports demonstrating that translated short peptides are responsible for the biological 
functions of the respective lncRNA (Matsumoto et al. 2017; Huang et al. 2017; Anderson 
et al., 2015; Nelson et al. 2016). However, Yu et al. (2017) reported that linc-RAM, a 
lncRNA that per se enhances myogenic differentiation by interacting with MYOD, is the 
transcript encoding myoregulin, a small peptide previously reported as a mediator of 
muscle performance through inhibition of the pump activity of SERCA (Anderson et al., 
2015). In this case, RNA and peptide functions cooperate in modulating muscle 
physiology. Intriguingly, in our model the lncRNA per se is responsible for most of the 
gene expression changes while the peptide might be responsible for specific functions 
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related to its cytoskeletal/junctional localization. I hypothesize that the peptide could 
participate in multiprotein complexes serving as permeability barriers and/or implicated in 
the establishment of apico-basal polarity as well as in the transmission of signals to the cell 
interior. Further studies will be needed to clarify the specific functions of the peptide but 
we can predict that EPR and the peptide might synergize in executing epithelial cell 
specific programs (Figure 8). 
EPR was discovered as a highly-regulated lncRNA in NMuMG mammary gland cells 
and, by exploiting the TGF-β-responsiveness of these cells, we were able to clarify some 
details of its molecular functions. How EPR influences normal physiology and disease in 
tissues undergoing repeated rounds of proliferation/differentiation, such as the gastro-
intestinal tract where it is highly expressed, will represent an important area of future 
research. 
Fig. 8. Distinct as well as complementary functions of EPR as noncoding RNA and 
EPR peptide 
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6. METHODS 
 
6.1 Cell lines 
Murine immortalized NMuMG cells (ATCC, no. CRL-1636) were cultured in DMEM 
plus 10% FBS and 10 μg/ml bovine insulin (Sigma-Aldrich), 4T1 mouse mammary gland 
cancer cells (obtained from ATCC, no. CRL-2539) and TS/A mouse mammary gland 
cancer cells (obtained from Dr. C. Bagni, VIB Center for the Biology of Disease) were 
cultured in DMEM/F12 plus 10% FBS, human mammary gland adenocarcinoma cells 
MDA-MB-231 (obtained from DSMZ, Germany, through Dr. G. Fronza, authenticated by 
STR DNA profiling) were cultured in DMEM plus 5% FBS, and human HEK-293 cells 
(ATCC, no. CRL-1573) were cultured in DMEM plus 10% FBS. NMuMG cells were 
maintained in DMEM supplemented with 2% for 16 hours prior to the addition of 10 ng/ml 
human recombinant TGF-β1 purchased from R&D Systems. 
 
6.2 Antibodies 
Anti-EPR polyclonal rabbit antibody was generated by injecting rabbits with 
recombinant purified EPR expressed in E. Coli using the pQE-EPR at Cambridge Research 
Biochemicals (Billingham, Cleveland, UK). Anti-CDH1 goat polyclonal antibody (sc-
31020), anti-CDKN1A mouse monoclonal antibody (sc-6246), and anti-HDAC1 rabbit 
polyclonal antibody (sc-7872) were from Santa Cruz; anti-TJP1 rabbit polyclonal antibody 
(ab96587), anti-SMAD3 rabbit polyclonal antibody (ChIP grade ab28379), anti-GFP rabbit 
polyclonal antibody (ChIP grade ab90) were from Abcam; mouse monoclonal anti-FLAG 
(F1804), mouse monoclonal anti-TUBA (DM1) and mouse monoclonal anti-ACTB (AC-
74) were from Sigma Aldrich. Mouse monoclonal anti-RNA Polymerase II (clone 
CTD4H8) and rabbit polyclonal antibody to H3K27me3 (CS200603) were from Millipore. 
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Rabbit polyclonal anti-CGN serum (C532) against a purified recombinant 50 kDa C-
terminal fragment of chicken cingulin as well as anti-CGNL1 rabbit polyclonal antibody 
(20893) were raised at the University of Geneve. 
 
6.3 Plasmids  
Plasmid EPR was obtained by inserting the sequence from nucleotide 1 to 1487 of 
murine BC030870 into pBICEP-CMV-2 vector (Sigma-Aldrich); plasmid h.EPR was 
obtained by inserting the sequence from nucleotide 4 to 1126 of human LINC01207 into 
pBICEP-CMV-2 vector; plasmids EPRMUTE and EPRMUTM were obtained by Site-
Directed Mutagenesis of plasmid EPR using the QuikChange II mutagenesis kit (Agilent 
Technologies) and the oligonucleotides: 
5′-CACCGTTAGTCTTCCATGTAGCTACCATTC-3′ 
5′-CACCGTTAGTCTTCCTAGTAGCTACCATTC-3′, respectively.  
Plasmids EPR-FLAG and EPRSTOPE-FLAG were generated by inserting the 
sequence from nucleotide 1 to 560 of murine BC030870 obtained by PCR and Flagged at 
its 3’ (either wild-type or mutagenized as above) into pIRES1hyg vector. Plasmids GFP-
mouse cortactin (#26722, CTTN-GFP) and CMV-GFP-human NMHC II-A (#11347, 
MYH9-GFP) were obtained from Addgene. Plasmid pQE-EPR was obtained by inserting 
the sequence from nucleotide 345 to 560 of murine BC030870 into into pQE-30 vector 
(Qiagen). 
For inserts obtained by RT-PCR, the Pfu DNA Polymerase (Promega) was used. The 
inserts cloned in all constructs were sequenced on both strands (BMR Genomics, Padova, 
Italy). 
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6.4 Cell transfections 
NMuMG, 4T1, and MDA-MB-231 cells were transfected with Lipofectamine 2000 
(ThermoFischer) while HEK-293 cells were transfected with Attractene transfection 
Reagent (Qiagen). NMuMG, 4T1, and MDA-MB-231 cells stably transfected with 
recombinant pBICEP-CMV-2-based vectors were maintained in selective medium 
containing 800 μg/ml, 350 μg/ml, and 750 μg/ml G418 (Sigma-Aldrich), respectively. 
NMuMG cells stably transfected with recombinant pIRES1hyg-based vectors were 
maintained in selective medium containing 600 μg/ml Hygromycin B (Sigma-Aldrich). 
Specific mock cells were generated (for every cell line and every plasmid backbone) by 
transfecting the corresponding empty vector in each cell type. Mock cells were subjected to 
a selection procedure identical to the other transfectants. siRNAs utilized to knock-down 
murine EPR (5′—GAGCAAAAGAGAAUGCUUA—3′) were purchased from Thermo 
Fisher. Stable KHSRP knock-down in NMuMG cells was obtained using previously 
described silencing sequences and pSuper-Neo (Oligoengine) according to manufacturer’s 
instructions (Puppo et al, 2016). The adenoviral vectors pAdCMVnull (AdNull) and 
pAdKHSRP (full-length human KHSRP cDNA cloned into an Adenoviral-Type 5 
backbone) were purchased from Vector Biolabs (Puppo et al., 2016). 
 
6.5 Scratch wound closure assay 
Either mock or EPR-overexpressing NMuMG cells were cultured in six-wells plates 
up to confluence and pretreated for 2 hours with 5 μg/ml Mitomycin C (Sigma-Aldrich). A 
wound was scratched into monolayers and cells were cultured for up to 48 hours in the 
presence of 5 μg/ml Mitomycin C. Images were taken using an Olympus CKX41 
microscope and analyzed using the ImageJ 1.49r package 
(http://imagej.nih.gov/ij/index.html). Average distance of wound obtained from six 
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microscopic fields was used for the calculation of percent wound healed. Experiments 
were performed three times in triplicate. 
 
6.6 Immunofluorescence 
Either mock NMuMG cells or stable transfectants overexpressing either EPR-FLAG 
or EPRSTOPE-FLAG were plated on glass coverslips in 24-well plates (60,000 cells/well). 
Immunofluorescence was carried out 2 days after plating essentially as reported in Spadaro 
et al., (2017). Rabbit polyclonal anti-cingulin antiserum (C532) was used at a 1/5000 
dilution while anti-FLAG antibody (F1804, Sigma) was used at a 1/500 dilution. 
Secondary antibodies were diluted in IF buffer and incubated for 30 minutes at 37°C, 
Alexa488 anti-rabbit (711-545-152, Jackson Laboratory) dilution 1/400, Cy3 anti-mouse 
(715-165-151, Jackson Laboratory) dilution 1/400. Pictures were taken using a Zeiss 
Axiophot widefield fluorescent microscope (X-Cite 120Q mercury lamp light source, 
Excelitas Technologies; retiga EXi, cooled mono 12-bit, Qimaging camera; 63x oil 
objective; Openlab software). Images were imported into ImageJ to split and merge 
channels, cropped and adjusted for resolution and for intensity level range using Photoshop 
(scale bar = 10 μm). 
 
6.7 Orthotopic 4T1 injection in BALB/c mice 
BALB/c 8–10-week-old female mice (Envigo) were anesthetized using 100 mg/kg 
ketamine and 10 mg/kg xylazine intra peritoneal. Eye lubricant was applied, hair around 
the abdominal and inguinal fat pads were trimmed and the skin was sterilized. With the aid 
of magnifying surgical loupes, a small incision of less than 3 mm was made externally and 
caudally to the fourth nipple with the tip of micro-dissecting scissors. The fourth mammary 
gland fat pad below was located and 100 μl of a suspension of either mock or EPR-
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expressing 4T1 cell were injected. uccessful injection is confirmed by the swelling of the 
tissue. The incision was then sutured. All procedures involving animals have been 
approved by Institutional Animal Welfare Body (O.P.B.A.) and respect the national current 
regulations regarding the protection of animals used for scientific purpose (D. Lvo March 
4th, 2014, n. 26, legislative transposition of Directive 2010/63/EU of the European 
Parliament and of the Council of September 22, 2010 on the protection of animals used for 
scientific purposes). Tumor length and width were measured using a digital caliper at day 
10 post-injection and tumor volume was calculated using the formula: volume = (length x 
(width)2/2). Mice were euthanized after two weeks and tumor masses were removed, 
weighted and photographed. 
 
6.8 Electrophoretic mobility shift assay 
Electrophoretic mobility shift assays (EMSA) were performed as detailed in Trabucchi 
et al., (2009). Production and purification of recombinant KSRP have been described 
previously in Briata et al., (2005). The labeled RNA was transcribed using Sp6 polymerase 
from a template generated by inserting into pCY vector a PCR product corresponding to 
nucleotides from 276 to 407 of murine BC030870. 
 
6.9 Isolation of RNA from cytoplasmic, nucleoplasmic, and chromatin 
fractions 
We followed the protocol recently published by Corey and coworkers (Gagnon et al., 
2014) starting from 10 x 107 cells. Both cytoplasmic and nucleoplasmic RNAs were 
precipitated and washed with ice-cold 70% (vol/vol) ethanol prior to be dissolved in 
QIAzol Lysis Reagent (Qiagen) while the chromatin pellets were immediately dissolved in 
QIAzol. Ten μl of 0.5 M EDTA were added to all the samples in QIAzol that were heated 
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to 65 °C with vortexing until dissolved (~10 minutes). The preparation of RNA was 
continued as described below. 
 
6.10 RNA preparation, quantitative RT-PCR, analysis of newly-
synthesized transcripts, and of mRNA decay 
Total RNA was isolated using either the miRNeasy mini kit (Qiagen) or QIAzol and 
retro-transcribed (50-100 ng) using Transcriptor Reverse Transcriptase (Roche) and either 
random hexamers or oligo-dT according to manufacturers’ instructions. Quantitative PCR 
was performed using the Precision 2X QPCR master mix (Primer Design), and the 
Realplex II Mastercycler (Eppendorf) according to manufacturers’ instructions. The 
sequence-specific primers utilized for PCR reactions are listed in Supplementary Table 1. 
In order to analyze gene expression changes among the pool of nascent mRNAs, we 
adopted the Click-iT Nascent RNA Capture kit (ThermoFischer) and performed 
experiments according to manufacturer’s instructions. NMuMg cells were pulsed with 0.5 
mM 5-ethynyl Uridine (EU) for 1 hour. In order to analyze mRNA decay we either 
blocked transcription by treating cells with 100 μM 5,6-Dichlorobenzimidazole 1-β-D-
ribofuranoside (DRB, Sigma-Aldrich) and isolating total RNA at different intervals of 
times or performing EU labeling-based pulse chase experiments labeling cells with 0.2 
mM EU for 16 hours, removing the culture medium, and chasing cells for 1 hour. RNA 
was prepared, “clicked”, retrotranscribed, and analyzed by qRT-PCR according to Click-iT 
Nascent RNA Capture kit instructions. 
 
6.11 Ribonucleoprotein complexes immunoprecipitation (RIP) assays 
RIP assays were performed as previously described (Giovarelli et al., 2014) with 
minor modification. Briefly, total cell lysates were immunoprecipitated with Dynabeads 
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(Thermo Fisher) coated with protein A/protein G and pre-coupled to specific antibodies at 
4o C overnight. Pellets were washed three times with a buffer containing 50mM Tris-HCl 
[pH 8.0], 150 mM NaCl, 0.5% Triton X-100, 1X Complete (Roche). Total RNA was 
prepared from immunocomplexes using the QIAzol Lysis Reagent, retro-transcribed, and 
amplified by qPCR as described above. The primer sequences are detailed in 
Supplementary Table 1. 
 
6.12 Protein identification by MALDI-TOF mass spectrometry (MS) 
analysis 
Total extract from either mock or EPR-FLAG (10 X 107 cells) were 
immunoprecipitated using anti-FLAG antibody-coupled Dynabeads. Immunoprecipitated 
material was analyzed by SDS-PAGE followed by silver staining. Protein identification 
was performed as a service at the Functional Proteomic Unit of IFOM (Milano, Italy; Drs. 
Angela Cattaneo and Angela Bachi). Bands of interest from SDS-PAGE were excised from 
gels, reduced, alkylated and digested overnight with bovine trypsin (Roche, Milan, Italy), 
as described (Shevchenko et al., 1996). One μl aliquots of the supernatant were used for 
mass analysis using the dried droplet technique and α-cyano-4-hydroxycinnamic acid as 
matrix. Mass spectra were obtained on a MALDI–TOF Voyager-DE STR mass 
spectrometer (Applied Biosystem). Alternatively, acidic and basic peptide extraction from 
gel pieces after tryptic digestion was performed and the resulting peptide mixtures 
subjected to a single desalting/concentration step before MS analysis over Zip-TipC18 
(Millipore Corporation). Spectra were internally calibrated using trypsin autolysis products 
and processed via Data Explorer software. Proteins were unambiguously identified by 
searching a comprehensive non-redundant protein database of the National Center for 
Biotechnology Information (NCBI, http://www.ncbi.nlm.nih.gov/) and the Mass 
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Spectrometry protein sequence DataBase (MSDB, http://msdn.microsoft.com/en-
us/library/ms187112.aspx), selected by default using in house the software programs 
ProFound v4.10.5 and Mascot v1.9.00, respectively. Protein identifications were accepted 
if they could be established at greater than 99.0% probability and contained at least 3 
identified peptides. Protein probabilities were assigned by the Protein Prophet algorithm 
(Nesvizhskii et al., 2003). Proteins that contained similar peptides and could not be 
differentiated based on MS/MS analysis alone were grouped to satisfy the principles of 
parsimony. 
 
6.13 RNA deep-sequencing (RNA-Seq) 
High-quality RNA was extracted from either mock, EPR-, or EPRSTOPE- 
overexpressing NMuMG cells (biological triplicates for each experimental condition), and 
a total of nine libraries were prepared using standard Illumina TrueSeq SBS PE 200 cycles 
protocol and sequenced on HiSeq2500. Image analysis and base calling were performed 
using the HiSeq Control Software and RTA component from Illumina. This approach 
yielded between 68 and 77 milions of reads that were further processed. Raw data have 
been published on the GEO archive under the Accession GSE113178 
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE113178). 
  
6.14 Analysis of h.EPR (LINC01207) expression in human samples 
Meta-analysis of RNA-Seq data of h.EPR in normal samples was performed by 
searching for h.EPR expression in different subpopulations of FACS-sorted normal breast 
cells (Pellacani et al., 2016) and in different human organs through either the Expression 
Atlas (https://www.ebi.ac.uk/gxa/home) or the GEPIA web server (http://gepia.cancer-
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pku.cn). h.EPR expression in breast cancer samples was analysed using TCGA data, 
deriving PAM50 classification from the original publication (Schmierer & Hill, 2005). 
 
6.15 Chromatin Isolation by RNA Purification (ChIRP) 
Chromatin Isolation by RNA Purification (ChIRP) was performed according to the 
protocol published by Chu et al. (2012) with minor modifications. Briefly, 2.5 X 107 
NMuMG cells were crosslinked in 20 ml of 1% glutaraldehyde in PBS at room 
temperature for 10 minutes on an end-to-end rotator. After glutaraldehyde quenching and 
repeated washes, cell pellets were weighted and resuspended in 1.0 ml of complete Lysis 
Buffer (50 mM Tris-Cl pH 7.0,  10 mM EDTA , 1% SDS, 1 X Complete, 500U RNAse 
inhibitor) per each 100 mg of cell pellet. Cell suspensions were sonicated for 90 min 
(power set to 70%) and the sonicated cell lysate was centrifuged at 16,100 x g at 4º C for10 
minutes. Lysates were divided into two 1 ml aliquots, transferred into polypropylene tubes, 
mixed with 2 ml Complete Hybridization Buffer (750 mM NaCl , 1% SDS,  50 mM Tris-
Cl, pH 7.0,  1 mM EDTA,  15% formamide, 1 X Complete, 1000 U RNAse Inhibitor) and 
hybridized with 1 μl (100 pmol) of either EVEN or ODD pools of 20-mer 3’ Bio-TEG 
DNA oligonucleotides designed with single-molecule FISH online designer (Stellaris) (see 
Supplemental Table 1), respectively. Hybridization was carried out at 37º C for 4 hours 
under continuous shaking. Seventy μl of pre-washed C-1 magnetic beads (Thermo Fisher) 
were added to each hybridization mixture for 30 minutes at at 37º C under continuous 
shaking. Beads were immobilized and washed four times for 5 minutes ar 37º C with 
shaking (wash buffer: 2 X NaCl and Sodium citrate (SSC), 0.5% SDS, 1 X Complete). 
While one aliquot (10% of the material) was utilized for RNA extraction, the remaining 
90% was subject to DNA purification by incubating two times each bead pellet with 150 μl 
Complete DNA Elution Buffer (50 mM NaHCO3, 1% SDS, 25 μg/ml RNAseA, 100 U/ml 
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RNAseH) for 30 min at 37º C with shaking. Eluted DNA was incubated with Proteinase K 
(1mg/ml final dilution) for 45 min at 50º C with shaking, extracted with 
Phenol/Chlorophorm/Isoamylalchool, Ethanol-precipitated, and aliquots were analyzed by 
qPCR. 
 
6.16 ChIP-qPCR 
The Magna ChIP A/G (Millipore, catalog # 17-10085) kit was used in combination 
with anti-Pol II, anti-H3K27me3, and anti-SMAD3 antibodies (and the corresponding 
control IgG). 
  
6.17 Sucrose-gradient fractionation and polysome profiling 
Experiments were performed as described (Zaccara et al., 2014). NMuMG cells (~70% 
confluence) were treated with cycloheximide (0.1 mg/ml) for 5 min at 37°C, washed twice 
with PBS supplemented by 0.01 mg/ml cycloheximide, scraped in PBS 1X with 0.01 
mg/ml cycloheximide, pelleted by centrifugation, lysed in 500 μl of ice-cold Lysis Buffer 
(Salt Solution 1X, 1% Triton-X100, 1% NaDeoxycholate, 0.2 U/μl RNase Inhibitor, 1mM 
DTT, 0.01 mg/ml cycloheximide), centrifuged for 5 minutes at 13000 rpm at 4°C, and 
supernatants were loaded onto sucrose gradients. One ml fractions were collected 
monitoring the absorbance at 260nm using a Density Gradient Fractionation System by 
Teledyne ISCO with sensitivity set to 0.2. Using the profile of the 260 nm absorbance, 
fractions corresponding to free ribosomal subunits (40S and 60S) and monosomes (80S, 
considered as not translating), separately from fractions corresponding to light polysomes 
(2-5 ribosomes) and heavy polysomes (>6 ribosomes) were pooled together and processed 
for RNA extraction and RNA was quantified by Nanodrop (Thermo Fisher). 
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6.18 Analyses of cell cycle distribution and quantification of S phase cells 
by flow cytometer 
NMuMg cells (either mock or EPR- or EPRSTOPE- transfected) were seeded in 6-
well plates. For the analysis by the CycletestTM Plus DNA Kit (BD Medical Technology), 
cells are detached by trypsinization and centrifuged in Eppendorf tubes at 300 Xg for 5 
min at room temperature. Supernatant is removed and the pellet is resuspended in 1 ml 1x 
PBS followed by centrifugation. Cells are then resuspended in PBS and counted using 
Countess® Automated Cell Counter and the cell concentration is adjusted to 7x105 cells/ml 
using the same buffer. The DNA staining procedure is performed using 0.5 ml of cell 
suspension (7x105 cells). Cells are pelleted by centrifugation (400 Xg for 5 min at RT). 
After carefully removing the supernatant, cells are mixed in Solution A (provided by the 
kit, containing trypsin in a spermine tetrahydrochloride buffer for digestion of cell 
membranes and cytoskeleton), without using a vortex. 200 μl of solution B (provided by 
the kit, containing trypsin inhibitor and ribonuclease A in citrate-stabilizing buffer, to 
inhibit the trypsin activity and to digest the RNA) is gently added and the sample is 
incubated for 10 min at RT, followed by the addition of 200 μl of cold solution C 
(provided by the kit, containing Propidium Iodide and spermine tetrahydrochloride in 
citrate stabilizing buffer). The sample is incubated in the dark and on ice for 10 min and 
then filtered by cell strainer caps and analyzed by flow cytometer (BD FACSAria II). Data 
on at least 10000 events for sample were processed using ModFit LT 4 software. The 
experiment was repeated two times. 
 To estimate more precisely the fraction of cells in S phase, the Click-iTTM Plus EdU 
Flow Cytometry Assay (Invitrogen) was used. EdU (10 mM stock in DMSO) was added 
directly to the culture medium at the 20 μM final concentration and incubated for 40 
minutes. Cells were then harvested by trypsinization and washed using 3 ml of PBS 
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containing 1% BSA. Pellets are resuspended in PBS + 1% BSA, counted using Countess® 
Automated Cell Counter and 1.5x106 cells are transferred to flow tubes, washed again with 
3 ml of PBS containing 1% BSA, pelleted by centrifugation followed by removal of the 
supernatant. Cells are resuspended in 100 μl of Click-iTTM fixative mixing well with a 
pipette and incubated for 15 min at RT in the dark. Cells are the washed as performed in 
the previous step, resuspended and incubated for 10 minutes in 100 μL of 1X Click-iTTM 
saponin-based reagent. Samples are then processed for the Click-iTTM reaction, preparing 
the Click-iTTM Plus reaction cocktail according to the manufacturer guidelines, adding 0.5 
ml of it to each sample, to reach a final volume of 600 μl containing 1.5x106 cells and 
incubating for 30 minutes at room temperature, in the dark. Cells are then washed once 
using 3 ml of 1X Click-iTTM saponin-based reagents, pelleted and resuspended in 600 μl of 
the same solution to which the Propidium Iodide staining solution is added to stain DNA. 
Propidium Iodide solution contains 50 μg/ml PI and 100 μg/ml RNAse. Samples are then 
analyzed by flow cytometer (counting 20000 events, BD FACSAria II). As controls, cell 
aliquots incubated with EdU and processed by the same protocol, but skipping the Click-
iTTM reaction or the PI staining, or both. 
 
6.19 G1 phase cell sorting 
Cells (mock, EPR, EPRSTOPE) were harvested by trypsinization when they reached 
~90% confluence, washed once in 1X PBS and resuspended in DMEM without serum at a 
concentration of 106 cells/ml. Hoechst 33342 (Thermo Fisher Scientific) was added to the 
media at the concentration of 10μg/ml and cells were incubated for 1 hour at 37°C. Cells 
were then centrifuged to remove Hoechst-containing media and resuspended in 1X PBS. 
Sorting was performed by BD Aria II cytometer (BD Bioscience) using a 100μm 
nozzle and setting a gate on the population of cells in G1. At least 90K events for every 
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sample were sorted in 1X PBS at room temperature. After sorting, purity was assessed by 
re-running the samples. Sorted cells were pelleted and immediately stored at -80C. RNA 
was extracted and analyzed by qRT-PCR as described above. 
   
6.20 Quantification of cell proliferation by high-content image analysis 
The proliferation of NMuMG cells (either mock or EPR- or EPRSTOPE- transfected)  
was quantified using Operetta High-Content Imaging System, acquiring images at different 
time points by digital phase contrast with a 40x objective. Images were analyzed using 
Harmony® High Content Imaging and Analysis Software. 500 cells were seeded in 96 well 
plates in triplicates. Pictures were taken at different time points, by automatically acquiring 
eight fields for each well. Data were analyzed in Excel and plotted as average and standard 
deviations of replicates. 
 
6.21 Quantification of cell proliferation by crystal violet staining 
For some experiments cell proliferation was assessed by crystal violet staining. At the 
indicated time after plating, cells were fixed (10% formalin) and stained (0.1% crystal 
violet) with crystal violet solution. After two washes with water, crystal violet staining was 
measured by spectrophotometer at a wave-length of 590 nm. 
 
6.22 Clonogenic and anchorage-independent cell growth assays 
For the clonogenic assays, cells were plated in triplicate on six-well plates at 500 cells 
per well and left to growth for 4-6 days. Cells were fixed and stained with crystal violet 
solution. Anchorage-independent cell growth assays was assessed according to the 
protocol published by Borowicz et al. (2014) with minor modifications. Briefly, 2500 cells 
were seeded in 0.3% Top Agar in complete medium and placed on a layer of 0.5% of 
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Bottom Agar in 12-well plates. Each cell line was seeded in sextuplicates and fed every 
three days. After 21 days cells were colored with crystal violet and photographs were 
taken. 
  
6.23 Quantification and statistical analysis of RNA-Seq 
Raw FASTQ reads were trimmed at the ends to remove low quality calls with FASTX 
[http://hannonlab.cshl.edu/fastx_toolkit]. Paired-End reads were aligned to indexed mm10 
genome with STAR (v 2.3.0e_r291). 
 To quantify expression levels mapped reads were counted from BAM files with 
HTSeq counts version 1.2.1, in “intersection-strict” mode, feature type “exon” and id 
attribute “gene_name” against reference annotation Ensembl GRCm38.74. 
 
6.24 Quantification and statistical analysis of transcript differential 
expression analysis 
In addition to gene-level analysis with STAR-HTSeq, the transcript abundance was 
further re-estimated using an alignment-free approach based on Kallisto 0.43.1 software, 
using Gencode Mouse vM15 transcripts as reference. 
Abundance files were imported in R.3.1.1 with TxImport.1.2.0 with option 
“txOut=TRUE” to quantify alternatively spliced transcripts. edgeR_3.16.5 and 
limma_3.30.13 were used to log2 transform transcripts count in Count Per Million (cpm). 
Only transcript with >= 1 cpm in at least 3 samples were retained. Cpm were transformed 
by library size and normalized by mean variance with limma-voom. Statistics and log-ratio 
were calculated with limma-eBayes, by fitting data to a single-factor linear-model with 
three different levels (mock, EPR, EPRSTOPE). 
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6.25 Venn Diagram 
We kept differentially expressed transcripts when the observed Bayesian statistic was 
significant (Benjamini and Hochberg corrected p-value < 0.01; logFC  > | 0.5 |). The 
functions limma-vennDiagram and pheatmap were used to cluster and visualize the 
significant genes. 
 
6.26 Gene Ontology and Pathway Enrichment 
Significant transcripts were summarized at gene level (tximport-summarizeToGene), 
annotated by Gene Ontology and enriched by statistically over-represented term with the 
EnrichR web-application using a nominal p-value threshold of p<0.01. The EnrichR p-
values refer to the Fisher Exact Test statistics, which is a proportion test that assumes a 
binomial distribution and independence for probability of any gene belonging to any set. 
 
6.27 Protein alignment 
Multiple alignment of mammalian EPR sequences was conducted by using the 
ClustalW2 package (ebi.ac.uk). 
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6.28  SUPPLEMENTARY TABLE 1. List of primers used for qRT-PCR and qPCR 
analyses as well as of 3’ Bio-TEG oligonucleotides used for ChIRP experiments. 
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